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1  Introduction 
 
In recent years, nanomaterials have received great attention in the areas of diagnostic and 
therapeutic healthcare.[1, 2] Nanomaterials are defined as materials with a dimension in the 
range of 1-100 nanometers.[3] These materials have been widely investigated for medical 
applications including diagnostic, drug delivery and tissue engineering.[1, 4] In the last 
decades diverse nanostructured materials have been vastly explored including quantum 
dots, superparamagnetic nanoparticles, liposomes, polymer based fibers and others.[5] These 
nanomaterials have not only been applied for the development of new diagnostic tools such 
as nanobiosensors, but also for therapeutic applications.[6], [7] Some of the materials have 
been discovered for various application at different time point (Figure 1) and many of them 
approved by the FDA such as Copaxone® (glatiramer acetate) used as an 
immunomodulator for the treatment of multiple sclerosis and Neulasta® a PEGylated 
granulocyte colony stimulating factor approved for chemotherapy induced neutropenia, but 
more are emerging in the clinical trials, such as CYT-6091 (PEGylated rh tumor necrosis 
factor (TNF) bound to colloidal gold) for solid tumor treatment.[1, 8, 9]  
 
 
Figure 1. Timeline for the discovery of the nanotechnology-based drug delivery. Reprinted 
with permission from Shi et al., Nano lett. 2010, 10, 3223-3230.[9] Copyright (2010) 




Currently, there is a rise in concern for its safety and biocompatibility that has to be 
addressed. From the material science point of view therapeutic efficacy, pharmacokinetics 
can be tuned by controlling several factors such as size, surface area, functional group 
composition and concentration.[10, 11] Biocompatibility of individual materials is dependent 
on the complex interaction with the extrinsic biological environment.[12] Size and nature of 
the materials determine the specificity of the interaction with plasma protein and play an 
important role for targeting and their clearance.[13, 14]  
It is obvious that the intrinsic properties of a target structure always determine the 
design of a synthetic ligand. The choice of an appropriate scaffold e.g. flexible vs. rigid 
architecture, branched vs. linear shape have to be considered. Apart from the scaffold 
architecture the number and type of functional groups of a nanomaterial have an impact on 
targeting and with respect to cytotoxicity and cellular uptake.[11, 15]  
























1.1  Multivalency 
 
Multivalency is a design principle that is often used by nature to achieve strong binding 
using weak univalent receptor – ligand interactions. It provides a strategy to convert a 
system having multiple, identical binding site into well-defined oligovalent species.[16-18] 
The prospect of multivalent interaction can be used to understand the evolutionary benefit 
of combining multiple existing interactions to increase the final affinities. A de novo 
redesign instead of stronger interacting molecules is not necessary.[17, 19, 20] The 
multivalency concept plays also a significant role in the development of new architectures 
in the areas of supramolecular, medical and material chemistry.[18, 21, 22] In case of perfect fit 
of ligand and receptor the degree of multivalency can potentiate the binding affinity.[17] 
A monovalent interaction affinity is calculated on basis of an association and 
dissociation constant. Multivalent interactions are often difficult to describe and therefore 
often mentioned as apparent affinities. Multivalency can be classified into bivalent (two 
binding partners), oligovalent (≤ 10) or polyvalent (> 10) interactions.[18]  
Whiteside et al. defined the enhancement factor as a ratio of Kd avidity and Kd affinity.[18] 
The enhancement factor can be explained by the thermodynamics of multivalent systems 
and a monovalent interaction. Thermodynamics tells us that an ideal equilibrium system 
exist as a result of minimizing free energy that could be achieved by low enthalpy and high 
entropy.[19, 23] According to the thermodynamic principle of multivalency, enthalpy of 
binding is additive while the translational and rotational entropy of interaction is 
unfavorable of binding.[18, 24] In the case of a multivalent nanomaterial the local 
concentration of the ligands is increased after first ligand-receptor interaction as the ligands 
are interconnected, which leads to a reduction of unfavorable entropic penalty.[17, 18] An 
interaction that causes enhanced binding enthalpy for the next ligand to receptor interaction, 
this type of enhancement is known as enthalpically enhanced binding.[16] One example from 
nature showing this type of binding is the interaction of  the pentavalent cholera toxin 
towards five ganglioside (GM1) ligands displayed on a cell surface.[25] In other scenario the 
binding of one ligand to an oligovalent receptor might cause steric hindrance for the next 
interaction. In this case, the binding is known as enthalpically diminished. This type of 






1.1.1  Multivalency in biological system 
 
Multivalency is strikingly common and a highly important factor seen in nature for 
achieving strong yet reversible interactions.[17] In many cases proteins arrayed on cells, 
bacteria, or viruses can bind strongly in a superselective fashion to their counterpart cell 
surface receptors.[16] As a consequence, these interactions trigger specific biological 
processes. To unravel the communication between biological systems is one of the miracles 
in molecular biochemistry and the principle of multivalency has been studied only for few 
decades.[16] Some of the examples of polyvalency, which are significant for human biology 
are – the adhesion of influenza virus to the cell surface via the interaction between multiple 
trimers of hemagglutinin and densely packed sialic acid on cell surfaces;[26, 27] the adhesion 
of E. coli pili proteins to host cell surface glycans (i.e. mannosylated structures);[28] and the 
adhesion of neutrophils to endothelial cells via interactions of multiple glycoproteins 
displaying the carbohydrate sialyl LewisX and the lectins E-, L- and P-selectin.[29] 
Biological systems instruct polyvalent interactions in many different situations because of 
some functional advantages such as clearance of pathogens, mediated by attachment of 
multiple antibodies to macrophages; interaction involving different ligand - receptor pairs 
causing enhancement in strength and specificity of interactions; polyvalent interactions on a 
large cell surface promote intimate conformal contact leading to efficient cell-cell 
communication.[16] In principle, polyvalent inhibitors can be designed to suppress undesired 
biological processes and in the best case to promote desired ones. Among the multivalent 
approaches some examples are inhibiting the attachment of influenza virus to host cell 
using polymers by entropically enhanced  binding or steric inhibition;[27, 30] polyvalent 
interactions inducing induction of signal causing promotion of desired interaction;[31] to 
facilitate the targeted imaging of tumor by utilizing the physiochemical parameters of the 
synthetic polymers.[14]  
 
1.1.2  Different ways to achieve polyvalency 
 
In order to harness the benefit of multivalency to rationally design new polyvalent ligands 
not only the intrinsic affinity of each ligand, but also their spatial orientation have to be 
considered. A common approach to achieve multivalent ligands is the choice of scaffolds, 
which could be flexible or rigid. A flexible scaffold provides wide conformational space to 
the system but thermodynamically speaking flexibility cause a huge loss in conformational 
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entropy during multivalent binding events.[16, 17, 32] Flexible backbones can be considered as 
a great choice to anchor ligand for multivalent binding. In the last few decades, linear or 
coiled structure having a certain degree of flexibility have been explored to attain the 
desired multivalent interaction.[17] Some of the examples of such scaffolds for polyvalent 
architectures and their uses are: polyacrylamides functionalized with sialic acid to inhibit 
the viral adhesion to the target cells by strong interaction and steric shielding of the 
virus,[27] ROMP (Ring Opening Metathesis Polymerisation) based linear polymers for 
signal transduction,[33] linear polyglycerols functionalized with sialic acid for inhibition of 
virus-cell interactions,[34] and semisynthetic polysaccharides consisting of a-1,6 linked D-
glucose.[35] Another scaffold choice is the rigid one where the possibility for loss of entropy 
is reduced, but the ligands need to be precisely oriented to avoid loss of enthalpy of 
binding. Depending upon the rigidity of the backbone entropy gain and loss can happen 
during ligand-receptor interaction. By perfect fitting and rigid arrangement an enhancement 
in affinity can be expected (Figure 2). 
 
 
Figure 2. Entropy loss in ligand-receptor interaction due to rigidity of backbone.	
Modified with permission from Koschek et al.[36]  
 
Limited flexibility in the backbone is achieved by radial arrangement of ligands e.g. 
dendrimers having almost defined architecture which could be functionalized on surface. 
Different chemical structure can be used to achieve dendritic architecture i.e. 
polyamidoamine dendrimers or hyperbranched polyglycerols. Some of the scaffolds used to 
design of polyvalent architectures are shown in Figure 3. In dendritic scaffolds to achieve 
Introduction 
 6 
optimum special orientation, the ligands are attached to the periphery through a spacer of 
optimal length. The choice of a linker is crucial for design of inhibitors in terms of length 
and other physiochemical characteristics. 
 
 
Figure 3. Examples of rigid and flexible scaffolds for polyvalent ligands: polyacrylamide 
ROMP, linear polyglycerol (lPG), dendritic polyglycerol (dPG), PAMAM dendrimer. 
 
A wide range of linkers were summarized by Whitesides et al. (Figure 4). In some 
cases flexible spacers such as (polyethylene glycol) are of great importance to achieve high 
binding affinity,[17, 37] but in some cases well designed conformationally nonflexible spacers 
can also help to achieve high affinity.[21] To design a perfect fit spacer or scaffold the 
distance between the binding sites of the receptors can be measured by spatial screening 
using DNA rulers.[38] Apart from designing multivalent binders, polymers are also involved 
to improve the bioavailability of available drugs by enhancing the circulation time 
(attachment of PEG to therapeutic agent) or by reducing the systemic toxicity of the drug 
(polymer as a delivery system). Apart from covalent systems a number of interesting 
scaffold made up of a discrete number of assembled subunits, known as supramolecular 
assemblies have been developed. The spatial organization of supramolecular architectures 
are supported mostly by noncovalent interactions like hydrogen bonding, van der Waals 





Figure 4. Examples of flexible and rigid linkers used in bivalent ligands: ethylene 
glycol,[40] alkyl,[41] polyglycine,[42] sacrosine,[43] diacetylene,[44] biphenyl,[45] proline,[46] 
DNA,[47] piperidine.[48] 
 
Among various interactions in supramolecular chemistry, host-guest interaction is an 
important phenomenon giving rise to models integrated in a facile and reversible 
manner.[49] Molecules like amphiphilic cyclodextrins (CDs) yielding unilamellar bilayer 
vesicles in aqueous solution, calixarenes, pillarenes, and cucurbiturils, possessing cavities 
can be explored as hosts for host-guest interaction (Figure 5).[50] Considering all the above 
factors we can say that a multivalent system is of great significance to render customized 







Figure 5. Chemical structure of cyclodextrin, cucurbituril, and calixarene and their 
schematic representation as host for supramolecular interactions. Reprinted with permission 



























1.2  Polyelectrolyte 
 
Polyelectrolytes are polymers containing ionizable groups that dissociate in aqueous 
solution. The free or substituted ionizable groups behave as partial or full salts and could be 
acidic (containing carboxylate, sulfonate, sulfate, or phosphate groups) or basic (amine 
groups).[51] Examples of charged biological macromolecules are DNA, RNA, polypeptides 
and polysachharides (e. g. heparin), whereas the synthetic electrolytes include polystyrene 
sulfonate and polyacrylic acid.[52] Self-assembled artificial polyionic complexes can be 
employed in biomedical applications due to their properties to form various structure i. e. 
micelles, layer-by-layer membranes, capsules.[53] Low toxicity is an additional benefit for 
polyelectrolytes as the complex is stablized by electrostatic forces and there is no need to 
involve many cross-linkers. Polyelectrolytes play a vital role in biological systems for 
interaction causing gene expression, cell-cell communications and ligand-receptor 
binding.[54, 55] Due to carrying both positive and negative charges, proteins can interact with 
the oppositely charged polyelectrolytes leading to precipitation or phase separation. In the 
formation of polyion complexes the entropy is a driving force as a large number of 
counterions are released, but these mechanisms are also affected by the various 
physiochemical properties of these polyelectrolyte. The thermodynamic information of the 
protein – polyelectrolyte interaction is well understood by isothermal calorimetry.[56] 
Interaction of proteins with various polyelectrolyte is well studied and reviewed, both 
theoretically and experimentaly by Ballauf et al. and the release of counterions was found 
to be the major driving force for protein interaction including linear and dendritic 
polyelectrolytes.[57] They proved the similar fact that binding is dominated by counterion 
release in a detailed study on binding of highly charged sulfated dendritic polyglycerol with 
human serum albumin.[58] There are many other challenges for biological electrolytes e. g. 
hydration mediated interaction at a very low distance from the electrolyte is not well 
understood, different couterions can cause different behavior of polyelectrolytes even if the 
charges are similar.[52, 55]  
 
1.2.1  Application of polyelectrolytes 
 
Polyelectrolytes can be broadly classified as positively and negatively charged 
macromolecules. Synthetic positively charged electrolytes are employed in gene delivery 
system, cationic lipid or polymers can form complexes with DNA (polyplex) and enter the 
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cell after interaction with the negatively charged plasma membrane of the target cells.[55] 
Further, the polyplex loaded endosome/lysosome mediates buffering of H+ and cause 
accumulation of chloride in lysosome leading to osmotic swelling and endosome lysis.[15] 
Via this route the content is delivered to the cytosol, compounds that needs to target the 
nucleus, must be further transported. Negatively charged polyelectrolyte are anionic 
macromolecules. One of the well-explored examples is sulfated dendritic polyglycerol used 
as an anti-inflammatory agent and other examples from natural origin are hyaluronic acid, 
heparin (highly sulfated glycosaminoglycan) and polysaccharides.[59, 60]  
 
1.2.2  Role of polysulfates in protein interaction 
 
Common anionic groups of charged polyelectrolyte are phosphate, carboxylate, sulfonate, 
and sulfate. Among these charged moieties, sulfates are widely explored for their function 
in biological systems. Sulfate can be defined as an oxidized form of sulfur and can be a 
source of sulfur containing metabolites.[61] The degree of sulfation and the linkage of 
sulfate to specific sugar residues of glucosaminoglycans (GAGs) defines their function. 
Sulfated GAGs of physiological significance are dermatan sulfate, chondroitin sulfate, 
heparin, heparan sulfate, and keratan sulfate. The only GAG, which is not sulfated, is 
hyaluronan. Chondroitin sulfates are glycosaminoglycans with a wide range of structure 
and show potential therapeutic properties.[62] Heparin is a polymer composed of highly 
sulfated polysaccharide. The molecular weight of unfractionated heparin ranges from 3 to 
30 kDa.[63, 64] It is widely used as an anticoagulant by binding to serine protease inhibitor 
(antithrombin III), preventing the formation of clots.[65] Limitations for the use of heparin 
include –  a short half-life, which causes frequent administration of heparin to achieve the 
desired effect,[65, 66] lack of adsorption in the gut so it needs to be administered 
intravenously or subcutaneously,[64] and common side effect like uncontrolled bleeding, 
pain, low platelet count.[64] Many unwanted side effects occur due to large number of 
heparin binding interactions. To solve this issue fractionation of low molecular weight 
heparin species has been developed by chemical or enzymatically controlled reactions.[67] 
Further, the synthetic analogue fondaparinux has been FDA approved.[68] Heparan sulfate 
structurally similar to heparin belongs to a family of linear sulfated, heterogenous 
polysaccharide.[69] Linked to protein, heparan sulfate proteoglycans play critical roles in 
various biological events due to their high degree of structural complexity. Heparan sulfate 
is located on the plasma membrane and is a part of the extracellular matrix and interacts 
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with a large number of different human proteins influencing the extracellular proteome and 
ultimately the cell function.[70] Heparin/heparan sulfate interacts with protein mostly via 
binding of negatively charge arising from carboxylate groups, O- and N- sulfates to 
positively charged amino acid e.g. lysine, arginine or protonated histidine.[71] Heparin and 
heparan sulfate are involved in binding and regulation of the activity of different proteins 
including enzyme, growth factors, and the cell surface proteins.[72] Heparin has also anti-
inflammatory activity by regulating the inflammatory response or modulating the 
complement activity. The ability of heparin/heparan sulfate and chondroitin sulfate to bind 




























1.3  Inflammation 
 
Inflammation is an early defense mechanism in response to microbial infection, disease and 
tissue damage that enables the removal of harmful stimuli.[73, 74] It is the body’s vital part of 
the innate immune system to fight against injury and infection in order to finally heal 
damaged tissue. Acute inflammation shows the classical known symptoms including 
redness due to hyperthermia swelling due to enhanced permeability of microvasculature, 
followed by leakage of protein into interstitial space, pain because of changes in 
perivasculature, and heat associated with increased blood flow and metabolic activity.[73, 75] 
Regardless of the reason, inflammation is always involved as an adaptive response to 
restore health. Generally, a controlled inflammatory response is beneficial by providing 
defensive action against external injury or foreign invaders, but it can be adverse if not 
regulated properly.[74] The entire reaction is subdivided into different processes including 
initiation, regulation and resolution of the inflammatory response. An acute setting involves 
migration of leukocytes to the site of injury.[74] In case of microbial infections the immune 
response is activated by a set of pattern recognition receptors including Toll-like receptors 
and various scavenger receptors expressed on macrophages.[76] The major ligands to these 
receptors include lipopolysaccharides, surface phosphatidylserine or modified low-density 
lipoproteins. Ligation of particles presenting these ligands leads to endocytosis and 
lysosomal degradation via scavenger receptors. Recognition via Toll-like receptors leads to 
intracellular signaling and results in enhancement of phagocytosis, release of cytokines, 
autacoids, lipid mediators or reactive oxygen species production that ultimately cause the 
amplification of a local inflammatory response.[77] In order to understand the complex 
network of inflammatory response, these signals are distinguished as inducer and mediator. 
The signals that can initiate the inflammatory response are defined as inducers while the 
signals that can alter the functionality of tissue and organ are known as mediators. Inducers 
could be exogenous or endogenous.[74] Exogenous inducer could be certain conserved 
molecular pattern carried by microorganism or virulence factor also known as microbial 
inducer and allergens, irritants, foreign agents included in the sub-category of non-
microbial inducers.[78] Endogenous inducer consists of signals due to stress and malfunction 
of tissues. These inducers trigger the production of inflammatory mediators, which can be 
further classified into seven categories including i) vasoactive amines (e.g. histamine), ii) 
vasoactive peptides (e.g. bradykinin), iii) complement fragments (e.g. anaphylatoxins: C3a, 
C4a, C5a), iv) lipid mediator (e.g. eicosanoids), v) pro-inflammatory cytokines (TNF-a, IL-
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1, IL-6) vi) chemokines that control the leukocyte extravasation, vii) proteolytic enzymes 
(elastin, cathepsin).[74]   
Acute inflammation results in the removal of infectious agents followed by a repair 
phase mediated by tissue residents and macrophages.[79] In case the trigger stimulus is not 
eliminated, the inflammation persists leading to a change in composition of infiltrating 
leukocytes from neutrophils to mononuclear phagocytes and T cells.[77]  
In a chronic inflammation the signals orchestrate a repertoire of responses such as 
recruitment of leukocytes (will be discussed in the next section), extracellular matrix 
remodeling, cellular proliferation, and angiogenesis giving rise to various diseases like 
atherosclerosis, obesity, asthma, neurodegenerative disease, and cancer. [80]  
 
1.3.1  Targeting inflammation via selectin 
  
Early adhesion of white blood cells through cell-surface glycoprotein interaction is one of 
the critical events for the recruitment of leukocytes into sites of inflammation. 
Extravasation of leukocytes is a multistep process initiated by the attachment and rolling of 
leukocytes over vessel walls mediated by various signaling and adhesion molecules like 
selectins (Figure 6), Ig-CAMs, integrins and chemokines.[81] The selectin family consists of 
three members: E-, P-, and L- selectin, which initiate and sustain the rolling of leukocyte on 
the endothelial cells. Selectins are the C-type lectins and are named according to their 
appearance. All three selectins are type-1 transmembrane glycoproteins consisting of a N-
terminal, calcium-dependent lectin domain, an epidermal growth factor domain, a variable 
number of complement regulatory units, a transmembrane domain, and a C-terminal 
intracellular domain.[82, 83] P-selectin and E-selectin are expressed on the vascular 
endothelial surface due to inflammatory stimuli with different expression kinetics.[83] E-
selectin expression is transcriptionally regulated. P-selectin is in addition also expressed on 
activated platelets and stored in intracellular vesicles.[83] L-selectin is constitutively 
expressed on leukocytes. All selectins promote the inflammation process by mediating 
leukocyte-endothelial interactions. Selectins show relatively weak, calcium dependent 
binding of the lectin domain to the tetrasaccharide sialyl Lewis x (SiaLex) and sialyl Lewis 
a (SiaLea). P-selectin glycoprotein ligand-1 (PSGL-1), which is a mucin like glycoprotein is 
expressed on leukocytes.[84] PSGL-1 is a well characterized ligand of all selectins and has a 
bi-ligand architecture. In addition to the  SiaLex carbohydrate epitope presented on an O-
glycan three sulfated tyrosine residues at the N-terminus of PSGL-1 are required for high 
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affinity binding to L- and P-selectin.[85] In contrast, E-selectin mediates PSGL-1 binding in 
a tyrosine sulfate-independent manner. The difference in binding affinities of E- vs. L- and 
P- selectin to PSGL-1 can be explained with the composition of the binding interface. In all 
selectins the carbohydrate binding area looks similar. Basic residues adjacent to the 
carbohydrate binding interface are solely present in L- and P-selectin and contribute to high 
affinity recognition of tyrosine sulfates of PSGL-1.[86] Moreover, binding avidity of 




Figure 6. Recruitment of leukocytes to the vascular endothelium is initiated by selectin-
ligand interactions and followed by transmigration of leukocytes from blood vessel to the 
site of inflammation. Adapted with permission from Wiley Materials: Fasting et al., Angew. 








1.3.2  Inhibitors of selectins 
 
 A therapeutic approach to treat chronic diseases could be the specific inhibition of selectin-
ligand recognition. Starting from the early days, monoclonal antibodies neutralizing E-, L-, 
and P-selectin were the first anti-selectin blocker.[88] After the finding that sialyl Lewisx the 
major ligand for selectins, Buerke et. al. developed sialyl Lewisx oligosaccharides as 
selectin inhibitors. Due to their short half-life time the sialyl Lewisx oligosaccharide was 
conjugated to liposomes and this formulation improved the potency by 25-fold.[89] Other 
multivalent SiaLex/a based inhibitors were decorated on a polylactosamine backbone or 
polyacrylamide based scaffold and supplemented with sulfated tyrosine residues.[90]  
Other than synthetic molecules natural glycosaminoglycans (GAGs) (Figure 7) has 
been known for years to be anti-inflammatory agents due to L- and P- selectin binding.[91] 
Rivipansel, a synthetic glycomimetic and a potential E-selectin inhibitor is an example for a 
small molecule, which is in clinical trial for the treatment of sickle cell anemia.[92] There is 
a demand for synthetic mimetics with desired properties and less side-effects.[93]  
 
Figure 7. Examples of structurally related glycosaminoglycans, which bind to L- and P- 
selectin. 
Inspired by interaction of PSGL-1 with all the three selectins, polysulfates were 
considered as potential anti-inflammatory compounds and a new class of molecules: 
sulfated polyglycerols was established. Dendritic polyglycerol sulfate proved to be a 
multivalent selectin binder and could inhibit the complement activation in vitro.[60] 
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Weinhart et al. proved that core size and degree of sulfation determine the binding 
affinity.[94]  
 
1.4  Atherosclerosis 
 
Atherosclerosis is defined as an age linked disease of large and medium sized arteries, 
characterized by hardening of the vessel wall and narrowing of the diameter, which can 
slowly block the arteries and can put blood flow at risk (Figure 8).[95]  
 
 
Figure 8. Healthy and diseased arteries showing plaque causing blockage of blood flow. 
 
Atherosclerosis is a leading cause of cardiovascular disease and one of the major burden of 
death in our westernized societies.[96],[97] Although the exact cause of atherosclerosis is still 
unclear, however, initial factors contributing to this injury include hypertension, high blood 
pressure, diabetes, smoking, obesity or high level of cholesterol in the blood. Mild 
atherosclerosis with gradual narrowing usually does not show any symptom for decades as 
the arteries enlarge on plaque formation, until the arteries is severely narrowed affecting the 
blood flow.[98] Some of the initial symptoms of narrowed arteries are pain or cramps due to 
hindrance in blood flow leading to lack of oxygen supply to the tissues and in case of 
sudden blockage of arteries it could lead to heart attack or stroke in brain. At a later stage, 
blockages can be diagnosed by electrocardiography and detection of cardiac markers, 
cholesterol or triglycerides levels in the blood. Based on which artery is affected 
atherosclerosis can cause diseases including i) coronary artery disease – when coronary 
arteries are hardened and prevent the flow of blood to the heart[99] ii) carotid artery disease 
– when an occluded carotid artery blocks the blood flow to the brain[100] iii) peripheral 
artery disease – when hardening of arteries prevent the circulation of blood in legs, arms 
and lower body[101] iv) kidney disease – when the blood flow in renal artery is reduced.[102] 
Mechanism of atherosclerosis can be explained as a series of events correlated to the 
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expression of adhesion molecules,[103] mononuclear cell recruitment to endothelium,[104] and 
activation of leukocytes leading to inflammation.[105] Apart from these findings the major 
characteristic feature of atherosclerosis is sub-endothelial accumulation of apolipoprotein B 
(apoB)–containing lipoproteins (LPs).[106] Recent studies suggest that atherosclerotic 
vascular plaque formation is significantly affected by the increase of oxidized low density 
lipoprotein (OxLDL) rather than native low density lipoprotein (LDL).[107] OxLDL uptake 
by macrophages causes the foam cell formation, which leads to the release of certain 
proinflammatory cytokines (Figure 9.).[108, 109] Inflammation and attack of leukocytes to the 
artery lumen of endothelium leads to formation of plaques in arterial tunica intima.[98, 107] 
Inflammation and other physiological factors could trigger the rupture of plaque and cause 
immediate occlusion or other cardiovascular disease.[110]  
 
Figure 9. Mechanism showing activation of AT1 and LOX-1 followed by cell dysfunction, 
apoptosis, monocyte activation and eventually atherosclerosis. Mehta et al. by permission 
from Oxford University Press. 
 
1.4.1  Scavenger receptor  
 
In 1979 scavenger receptors (SR) were first described by Goldstein and Brown.[111] SR 
constitute a superfamily of membrane bound receptors and are involved in a wide range of 
biological functions. These receptors were initially thought to participate in binding and 
internalisation of modified low density lipoprotein but later on the studies revealed that SR 
are involved in binding to endogenous proteins, lipid transport, pathogen clearance, cargo 
transport within cell and even as taste receptor.[112, 113] SR are integral membrane proteins 
expressing isoforms of soluble receptors. The common feature of all the scavenger 
receptors is their binding ability to common negatively charged ligands like phospholipids, 
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apoptotic cells, cholesterol ester, carbohydrates, lipoprotein. Binding of the scavenger 
receptor to lipid particles, subsequent uptake and intracellular storage leads the macrophage 
differentiation into foam causing enhancement of atherosclerotic condition.[113, 114] Based 
on the structure and biological activity, scavenger receptors are classified into ten classes A 
to J (Figure 10). Zani et al. have well summarized the classification of the scavenger 
receptors based on structure and biological functions.[115]  
Among all the classes of scavenger receptors Class E SRs are well studied and 
explored for their critical role in the initiation of atherosclerosis. Class E SR are type II 
membrane protein and consists of four domains: N- terminal cytoplasmic domain, 
transmembrane domain, neck region, and C-terminal carbohydrate recognition domain. 
They are expressed mainly on endothelial cells but also found on vascular smooth muscle 
cells and macrophages. Major ligand for class E SRs are OxLDL, phosphatilydserine and 







Figure 10. Overview of the classification and structural characteristics of SR. Adapted 








1.4.2  LOX-1  
 
In 1997, a class E scavenger receptor for oxidised low density lipoprotein was discovered in 
endothelial cells[118] and defined as LOX-1. It is a membrane bound type II glycoprotein 
and belongs to C-type lectin superfamily. Structurally speaking, LOX-1 consists of four 
domains: N-terminal cytoplasmic domain, single transmembrane domain, NECK domain 




Figure 11. Primary structure of human LOX-1 showing four domains: cytoplasmic domain, 
transmembrane (TM), NECK domain and CTLD domain with intrachain disulfide bonds. 
Reprinted from Ohki et al.[120] Copyright (2005), with permission from Elsevier. 
 
Special structural feature of the CTLD domain is its sequence homology to C-type 
lectin, which can recognize and bind to specific carbohydrate ligands. Another structural 
features are the three conserved intrachain disulfide bonds stabilizing the CTLD fold and a 
interchain disulfide bond between monomers via cysteine at 140 position.[121] In the cellular 
environment LOX-1 is expressed as a noncovalent oligomer of homodimers connected via 
disulfide bond at C140. A threshold expression level is necessary to mediate a significant 
binding of ligands.[122] Based on the crystal structure analysis the length of the dimeric 
CTLD surface is approximately 7 nm. The formation of oligomeric dimers is described 
(Figure 12.).[119-121] The C-terminal lectin like domain plays a critical function for ligand 
recognition, binding, and cargo internalisation.[120] In the absence of the lectin domain 
LOX-1 loses the function of recognition and binding to the negatively charged ligands. 
Over the dimer surface there is a linear arrangement of arginine residues, which is defined 
as “basic spine”. Due to basic spine, the CTLD domain is positively charged and 
cooperatively recognizes negatively charged molecules including oxLDL, apoptotic cells, 
and poly-anions.[123] The arginine residue of basic spine plays a very important role in 






Figure 12. Dimer of LOX-1 expressed on the cell surface (A) Dimer of LOX-1 showing 7 
nm of CTLD dimer length based on the crystal structure. (B) Comparison between size of 3 
clustered LOX-1 dimers and an oxLDL particle. (C) Top-view of the dimer consists of 
linearly aligned arginine residues (in blue). Reprinted from Ohki et al.[120] Copyright 
(2005), with permission from Elsevier. 
 
The Neck region connecting the CTLD to the transmembrane domain is important 
for the formation of homodimers via an interchain disulfide bond and contributes to further 
oligomerization. The extracellular domain of LOX-1 is a heart shaped homodimer, is 
modified by N-linked glycosylation, and constitutes a central hydrophobic tunnel to 
accommodate hydrophobic ligand structures. The N-terminal cytoplasmic domain is 
involved in intracellular signal transduction.[108] LOX-1 was first detected on endothelial 
cells but it is also expressed on macrophages, smooth muscle cells, and platelets.[124] The 
basal cellular expression of LOX-1 is quite low but the expression can be induced by 
various signals including pro-oxidative, pro-inflammatory and mechanical stimuli. 
Angiotensin II is an important factor for upregulation of LOX-1 via ATI receptor activation 
and enhances the uptake of oxLDL.[125] Oxidant species like H2O2 leads to an upregulation 
of LOX-1 expression in endothelial cells, smooth muscles cells, and fibroblasts. In vitro 
many pro-atherogenic factors like oxLDL, tumor necrosis factor, high glucose and C-
reactive protein cause the upregulation of LOX-1.[126]  In vivo, LOX-1 upregulation could 








1.4.3  Role of LOX-1 in pathological states 
 
Binding of oxLDL to LOX-1 induces endothelial cell activation followed by dysfunction of 
endothelial. Additionally, oxLDL stimulates the expression of chemokines and adhesion 
molecules, which facilitates the initiation of atherosclerosis.[128] LOX-1 expression causes 
induction of hypertension via participating in the genesis of diminished endothelium-
dependent vasorelaxation.[129] LOX-1 expressed on platelets could lead to internalisation of 
oxLDL followed by reduced eNOS activity and enhanced platelet aggregation. In this way 
LOX-1 can play an important role in oxLDL mediated platelet activation leading to 
thrombosis.[130] LOX-1 also supports the adhesion of Gram-positive and Gram-negative 
bacteria to vascular endothelial cells leading to bacterial inflammation.[131] LOX-1 also 
plays a role in oxLDL induced smooth muscle cell proliferation, apoptosis and foam cell 
formation.[132] Pathogenesis of myocardial ischemia after a short coronary artery occlusion 
followed by reperfusion involves the role of LOX-1.[133, 134] LOX-1 contributes to 
inflammation in a bi-functional way by overexpression of pro-inflammatory cytokines and 
utilization of oxLDL.[135] Additionally, LOX-1 interaction with oxLDL leads to expression 
of cytokines like interleukin-1β and tumor necrosis factor α which further expresses 
adhesion molecules including VCAM 1, ICAM 1.[136] Taking into account all the above 
mentioned effects the involvement of LOX-1 for initiation and progression of 
atherosclerosis is obvious. A blockade of the LOX-1 receptor leads to an improvement in 
cellular function, suggesting LOX-1 as a potential therapeutic target for prevention of 
atherosclerosis and other cardiovascular diseases (Figure 13).[137] LOX-1 exhibit a broad 
ligand specificity.[138] The protein was identified as a receptor for oxLDL but later, in vitro 
studies showed that LOX-1 can also binds to other chemically modified lipoprotein such as 
acetylated LDL, hypochlorite-modified high-density lipoproteins, carbamylated LDL and 
remnant-like lipoprotein particles.[116, 138, 139] Further, LOX-1 also recognizes ligands, which 
does not share any similarities with lipoproteins such as polyanionic moieties including 
heparin, dextran sulfate, polyinosinic acid.[138] Anionic phospholipids like 
phosphatidylserine, phosphatidylinositol and phosphatidylglycerol seems to work as a 
ligand for LOX-1.[116, 138] Cellular ligands such as activated platelets, aged/apoptotic cells, 
bacteria have been explored as a ligand for LOX-1.[131, 140] According to the recent findings 
C-reactive protein (CRP) an acute-phase protein expressed in response to inflammation and 





Figure 13. Illustration of potential disease states where an anti-LOX-1 therapy can be of 
potential therapeutic benefit. Reprinted from Pothineni et al., J. Am. Coll. Cardiol., 2017, 
69, 2759-2768,[134] Copyright (2017), with permission from Elsevier. 
 
1.4.4  LOX-1 modulators 
 
In the last few decades LOX-1 is explored as a novel therapeutic target in cardiovascular 
disease and wide research is under process to identify and pharmacologically characterize 
compounds for modulation of LOX-1.  
Various categories of ligands are studied as LOX-1 modulators such as  
i) Naturally occurring compounds: tanshinone II-A an active derivative of herbal drug 
can inhibit LOX-1 and ox-LDL uptake, curcumin- an active ingredient of turmeric 
inhibits Ang-II mediated overexpression of LOX-1.[142, 143] Various other natural 




ii) Synthetic modulators for LOX-1: Primary binding site for the interaction of 
phospholipid moieties of oxLDLD and LOX-1 is the hydrophobic tunnel in the dimer of 
the receptor, moieties that can fit properly in this hydrophobic tunnel can block LOX-1 
and oxLDL binding. In this direction modified lipid were developed by Falconi et.al. 
and small chemical inhibitors were screened by structure based drug design techniques 
and the selected molecules were evaluated for their efficiency to reduce oxLDL uptake 
and LOX-1 mRNA expression.[145, 146] 
iii) Other cardiovascular drugs: In addition to specific LOX-1 inhibitors other 
compounds including antihypertensive agents like calcium channel blockers 
(amlodipine, statins), anti-inflammatory drug like aspirin or NF-kβ inhibitor 
(pyrrolidine dithiocarbamate), antihyperglycemic agents like metformin or gliclazide 
demonstrate modulatory effects and a reduction in oxLDL mediated expression of 
LOX-1.[127, 147-149] 
iv) Various food stuffs rich in procynidins including grape seed or apple could 
potentially inhibit the uptake of oxLDL.[150]  
v) A specific inhibition of LOX-1 can also be done by monoclonal antibodies, use of 
these antibodies has shown to cause a reduction in oxLDL uptake but due to the adverse 
effect from immune response these antibodies are challenging to use in humans.[151]  
Understanding the complex mode of action of LOX-1, its contribution towards 
cardiovascular disease development including atherosclerosis, the wide range of ligand 
binding, and modulation of LOX-1 activity is challenging, but can be addressed by the 






Figure 14. Examples of LOX-1 modulators 1. Natural modulator (i) Tanshinone II-A,[142] 
(ii) curcumin.[143] 2. Synthetic modulators (i) PLAzPC (modified oxidised 
phospholipid),[146] (ii) small molecule discovered by virtual screening.[152] 3. Other 











2  Scientific Goal 
 
The concept of multivalency is widely spread in biological systems and it is utilized to 
enhance single interactions of low affinity. The Haag group has well explored dendritic 
polyglycerols as a scaffold for further functionalization. Polyglycerol based dendritic 
structures are of high interest due to their tunable chemical properties. Another multivalent 
scaffold is supramolecular vesicle of b-cyclodextrin, a cyclic oligosaccharide consisting of 
D-glucopyranose as repeating unit. The special orientation of the repeating units creates a 
conical shaped hydrophobic cavity. This host system can bind guest molecules like 
adamantane. Assembled into a spherical architecture a multivalent scaffold is generated. 
Sulfate is used as a targeting moiety to further functionalize both scaffolds.  
It was the aim of this thesis to develop, characterize and evaluate multivalent sulfated 
dendrons targeting the basic, positively charged surface of two proteins:  L-selectin and 
LOX-1.  
In the first part of the thesis cyclodextrin vesicles shall be functionalized with sulfated 
oligoglycerol dendron conjugated to adamantane, and all the host-guest complex will be 
analysed regarding their physiochemical properties by ITC (isothermal calorimetry) and the 




Figure 15. Overview for the main objective of first part of thesis 
 
In the second part of thesis polyethylene glycol bifunctionalised with sulphated dendrons 
shall be synthesised and evaluated for the binding behaviour with LOX-1. Cell based in 
vitro studies will also be conducted to gain more information about potential binding 
molecules. Additionally, the synthesized molecules will also be analyzed for toxic 
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3  Publication and Manuscript 
 
This chapter lists the published article as well as submitted manuscripts and specifies the 
contribution of author. 
 
3.1  A toolbox approach for multivalent presentation of ligand–receptor 
recognition on a supramolecular scaffold 
 
Svenja Ehrmann1, C.-W. Chu1, Shalini Kumari1, K. Silberreis, C. Böttcher, J. Dernedde, 
B. J. Ravoo*, and R. Haag* Journal of Material Chemistry B 2018, 6, 4216-4222. 
1 Authors contributed equally 
http://dx.doi.org/10.1039/C8TB00922H 
 
A supramolecular toolbox approach for multivalent ligand–receptor recognition was  
established based on β-cyclodextrin vesicles (CDVs). A series of bifunctional ligands for 
CDVs was synthesised. These ligands comprise on one side adamantane, enabling the 
functionalisation of CDVs with these ligands, and either mannose or sulphate group 
moieties on the other side for biological receptor recognition. 
 
 
Figure 17. Adapted with permission from The Royal Society of Chemistry: Ehrmann et al. 
J. Mat. Chem. B. Copyright 2018. 
 
In this publication the author contributed in the parts of concept, synthesis and 
characterization of sulfated glycerol based dendron conjugated to adamantane ligand and 
binding analysis of the sulfated architecture with L-selectin by MST and the preparation of 
manuscript. 
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3.2  Design and Synthesis of PEG-Oligoglycerol Sulfates as Multivalent 
Inhibitors for the Scavenger Receptor LOX-1 
 
Shalini Kumari, Katharina Achazi, Pradip Dey, Rainer Haag, Jens Dernedde* Submitted 
Manuscript ID: bm-2018-014162. 
 
Reprinted with permission from (S. Kumari, K. Achazi, P. Dey, R. Haag, J. Dernedde, 
Biomac. 2019. Copyright (2019) American Chemical Society.   
 
 
Figure 18. Graphical abstract for the above manuscript. 
 
In this publication the author contributed with the concept, synthesis and characterization of 
PEG conjugated sulfated glycerol based dendron, binding analysis of the sulfated polymers  
with LOX-1 by SPR, proving the concept by cell-based assay and the preparation of 
manuscript
Design and Synthesis of PEG-Oligoglycerol 
Sulfates as Multivalent Inhibitors for the 
Scavenger Receptor LOX-1 
Shalini Kumari,a Katharina Achazi,a Pradip Dey,a Rainer Haag,a Jens Derneddeb*
aInstitute for Chemistry and Biochemistry, Freie Universität Berlin, Takustr. 3, 14195 Berlin, 
Germany. 
bCharité-Universitätsmedizin Berlin, Institute of Laboratory Medicine, Clinical Chemistry 
and Pathobiochemistry, CVK, Augustenburger Platz 1, 13353 Berlin, Germany 
KEYWORDS: scavenger receptor, LOX-1 inhibitor, cardiovascular disease, PEG, 
polyglycerol sulfate.
ABSTRACT 
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a cell surface scavenger 
receptor. The protein is involved in binding and internalization of oxidized low-density 
lipoprotein (oxLDL), which leads under pathophysiological circumstances to plaque 
formation in arteries and initiation of atherosclerosis. A structural feature of LOX-1 relevant 
to oxLDL binding is the “basic spine” motif consisting of linearly aligned arginine residues 
stretched over the dimer surface. Inhibition of LOX-1 can be done by blocking these 
positively charged motif. Here we report on the design, synthesis, and evaluation of a series 
of novel LOX-1 inhibitors having different number of sulfates and PEG spacer. Two 
molecules, compound 6b and 6d showed binding affinity in the low nM range i. e. 45.8 and 
47.4 nM, respectively. The in vitro biological studies reveal that these molecules were also 
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able to block the interaction of LOX-1 with its cognate ligands oxLDL, aged RBC, and 
bacteria. 
INTRODUCTION 
Scavenger receptors (SR) were first identified by Goldstein and Brown as membrane 
receptors that bind and internalize modified low density lipoproteins.1 According to recent 
findings, these receptors belong to a large family of membrane-bound receptor and recognize 
a variety of ligands such as lipoproteins, apoptotic cells, cholesterol ester, and bacterial 
lipopolysaccharide.2 Based on their structure and function SR proteins are classified into 
various classes (class A-J).3 In 1997, Sawamura et al. discovered a class E scavenger 
receptor, designated as lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), 
which is mainly expressed on endothelial cells.4 Besides endothelial cells, LOX-1 is also 
present on macrophages, platelets and smooth muscle cells and is responsible for binding and 
internalization of oxLDL.5,6 Pathobiological studies revealed that LOX-1 is involved in 
oxLDL internalization through receptor-mediated pathways.7,8 Recent studies indicate that 
the focal accumulation of lipid-laden foam cells, derived from macrophages due to oxLDL 
uptake, is a critical event in the early stages of atherosclerosis. The disease is defined by 
hardening and narrowing of arteries and can put blood flow at risk.9 Pro-inflammatory stimuli 
originate from damaged endothelial cells and sub-endothelial remodeling processes and 
induce a cascade of events at the early step in atherogenesis.10,11 Ongoing vascular occlusion 
and finally plaque rupture therefore lead to cardiovascular problems and are the major cause 
of death in western societies.12,13,14 Among other risk factors including hypertension, 
diabetes, smoking, and obesity the sub-endothelial accumulation of lipoprotein particles is of 
prime interest, calling for the development of an efficient strategy to block oxLDL uptake.15 
LOX-1 is a 52-kDa type II membrane glycoprotein and consists of four domains - an N-
terminal cytoplasmic domain, a transmembrane domain, a neck region, and the C-terminal 
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extracellular C-type lectin-like domain.16 The basal complex contains two individual LOX-1 
polypeptides linked via an intermolecular disulfide bond bridge in the neck domain (C140)17. 
The structural feature of LOX-1 known as “basic spine”, consisting of linearly aligned 
positively charged arginine residues stretched over the dimer surface, is responsible for 
oxLDL particle recognition via interaction with negatively charged components of 
oxLDL.17,18 In addition, a hydrophobic tunnel is important for lipid binding.19
With respect to a therapeutic approach, the design of specific inhibitors for LOX-1 that 
antagonize oxLDL uptake might be beneficial to treat cardiovascular disease and reduce the 
acute inflammatory response. Additionally, LOX-1 inhibitors might be applicable as 
bacteriostatic agents by avoiding bacterial adhesion. Natural substrate mimetics or structure-
based design of LOX-1 inhibitors have been reported to inhibit LOX-1 activity by targeting 
the hydrophobic tunnel.20,21 The known LOX-1 inhibitors are mainly based on small 
molecular drugs and hydrophobic moiety. Therefore, bioavailability is very less and until 
now, there is no multivalent inhibitor available, which can target LOX-1 specifically. 
In recent years, we have shown how a rational design of multivalent entry inhibitors for 
pathogens such as viruses and bacteria can be applied to block and reduce infectivity. The 
effectiveness of the inhibitors not only depended on the nature of functional groups (specific 
interaction such as mannose - Concannavalin A,22 hemagglutinin - sialic acid23) or charges 
(electrostatic interactions like sulfates with L-selectin24) but also the size and multivalency of 
the architectures e.g., dendritic versus linear polymers,25 polymeric hydrogel particles,26 2D 
graphene sheet27 etc. played an important role in increasing the affinity towards the target.28 
In this work we present a novel class of multivalent inhibitors based on AB type diblock and 
ABA type triblock dendron polymer conjugates for the inhibitor of LOX-1. The inhibitor 
design is based on the given structure of the ligand binding site i.e., the linearly aligned 
arginine residues on the surface of the lectin-like domain. It has been previously reported that 
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mutations of arginine residues from the basic spine markedly reduce LOX-1 binding activity 
of oxLDL.29 In LOX-1 the approximate distance between the basic patches of dimeric 
surfaces is 7 nm (Figure 1).16, 17 To completely shield and effectively bind to LOX-1 a 
flexible handle/thread is needed which can stretch over the dimeric surface and span 
approximately 7 nm. In our design, the block (A) is composed of an anionic oligoglycerol 
dendron where the number of anionic sulfate groups can be varied based on the dendron 
generation while block (B) is a linear polyethylene glycol (PEG) polymer of 6 and 10 kDa 
(Figure 2). To support the inhibition of an acute inflammatory response, sulfates were chosen 
as anionic ligands inspired from dendritic polyglycerol sulfates (dPGS) which are known as 
multivalent inhibitors of inflammation, previously reported by our groups.24 A PEG spacer 
was chosen due to its biocompatibility and convenience for functionalization at both 
ends.30,31,32 The resulting macromolecules were analyzed for binding to recombinant LOX-1 
by surface plasmon resonance (SPR). In addition, two lead molecules were evaluated for the 
ability to inhibit the interaction of LOX-1 with its other natural ligands: aged RBC, oxLDL 
and bacteria. 
Figure 1. Top-view of LOX-1 showing positive patches of basic spine. Adapted from 
Thakkar et al.33 
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Figure 2. Structures of synthesized architectures 
EXPERIMENTAL SECTION 
Recombinant protein expression 
In order to prepare the soluble protein, LOX-1 coding sequences were inserted into a 
derivative of the mammalian expression vector pFLAG-CMV-3 (Sigma-Aldrich). Expression 
of the full length membrane bound LOX-1 was realized from a pCDNA6/V5 His A derived 
(Thermo Fisher Scientific) recombinant expression plasmid. Detailed information is given in 
the Supporting information (SI). In brief, coding sequence was amplified via polymerase 
chain reaction (PCR) from a LOX-1 cDNA clone (Sinobiological, Gene Bank Ref. ID: 
NM_002543.3). To mimic essential oligomerization LOX-1 was expressed as fragment 
crystallizable (Fc) fusion protein carrying one or two aligned C-type lectin domains (CTLD) 
of LOX-1 fused to an IgG1 heavy chain. 
Transient secreted protein expression was performed in the human embryonic kidney cell line 
in HEK293 cells after DNA transfection using Lipofectamine 3000 (Thermo Fisher 
Scientific) according to the manufacturer’s protocol. Proteins 1CTLD-Fc and 2CTLD-Fc, 
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representing a divalent and tetravalent LOX-1 architecture, were purified from the 
supernatant on a Protein A sepharose (Thermo Fisher Scientific) column. After extensive 
washing with phosphate buffer saline (PBS) bound protein was eluted from the column with 
elution buffer (20 mM citrate, 150 mM NaCl, pH 2.5). The eluted protein was immediately 
neutralized by dropping into a prepared 1 M Tris solution, pH 8.0. Protein samples were 
further concentrated and equilibrated with washing buffer (PBS) by filtration (Amicon 
concentration device 10K). The protein samples were analysed by SDS-PAGE under non- 
reducing and reducing conditions. HEK293 cells were cultured in 10% DMEM supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 oC in 5% CO2 
Binding assay - surface plasmon resonance measurements 
Binding analyses of the synthesized molecules was performed by surface plasmon resonance 
(SPR) on a BIACORE X100 (GE Healthcare) at 25 °C. 2CTLD-Fc was immobilized on a 
protein A chip (BIAcore). Briefly, 2CTLD-Fc was dissolved in the HBS-Ca buffer solution 
(10 mM HEPES, pH 7.5, 150 mM NaCl, 1mM CaCl2), and its concentration was adjusted to 
60 µg/ml. The 2CTLD-Fc was injected at a flow rate of 10 µL/min for immobilization. 
Ligand binding was recorded in HBS-Ca buffer at a flow rate of 30 µL⁄min with an 
association phase of 180 sec and a dissociation phase of 180 sec. Regeneration of the chip 
surface was performed by injection of 10 mM glycine-HCl, pH 1.5 at 100 µL⁄ min for 60 sec. 
Applying the single cycle kinetic approach five increasing ligand concentrations were passed 
over the LOX-1 functionalized surface without any regeneration procedure in between. Rate 
constants were calculated by using the BIAevaluation software 4.1.  
Inhibition assays - Red blood cells (RBC) and LOX-1 binding inhibition. 
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Binding of aged RBC to LOX-1 was evaluated according to a previously reported protocol 
with slight modification.34 Briefly, RBC isolated from fresh human blood and were washed 
three times with PBS. Thereafter, 20 % hematocrit was resuspended in PBS containing 0.1 % 
w/v of glucose and which was used as native RBC fraction. To produceaged RBC 20 % 
hematocrit was incubated at 37 °C for 4 days. To perform the assays RBC (aged or native) 
were fixed with 4 % formaldehyde and 0.2 % glutaraldehyde solution in PBS, and washed 
three times with PBS. Thereafter, 50 µL of 1 % hematocrit dissolved in Ham’s F-12 medium 
containing 10 % fetal bovine serum were incubated for binding studies with 50 µg/mL of 
2CTLD-Fc. In competition experiments the LOX-1 fusion protein was preincubated for 90 
min at room temperature with compound 6d  or an inhibitory monoclonal antibody (mAB, 
R&D systems) at a concentration of 100 µg/mL. Treated RBC were then washed three times 
with medium and further incubated with FITC-labelled Protein-A (Invitrogen) for 30 min at 
room temperature and subjected to fluorescence microscopy and flow cytometry after three 
times washing with medium. 
LOX-1 mediated recognition of E. coli 
LOX-1 plays an important role in recognition and binding of Gram positive and Gram 
negative bacteria. Here we analyzed E. coli (DH5α) recognition by LOX-1 transformed cells 
and monitored the inhibitory effect of compound 6d according to the reported protocol with 
partial modification.35 Briefly, HEK293 cells (1x106 cells) were seeded on slides (ibidi) and 
transiently transfected for full length LOX-1 expression using Lipofectamine 3000 (Thermo 
Fisher Scientific) according to the manufacturer’s protocol. E. coli was labeled with 
fluorescein isothiocyanate (FITC) (Sigma) according to a reported protocol, 36 detailed 
information is provided in the SI. Transfected HEK293 cells and non-transfected control cells 
were incubated with FITC-labelled E. coli (3x107 cells/mL) in the cell culture medium at 37 
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°C for 1 h. For inhibition studies cells were pretreated with polyinosinic acid (Poly(I)) (100 
µg/mL) and compound 6d (100 µg/mL) for 15 min before FITC-labelled bacteria were 
added. During two washing steps with PBS unbound bacteria were removed. The adherence 
of bacteria was further visualized by fluorescence microscopy (Axiophoto 2; Zeiss). Cells 
were treated with trypsin for 5 min, and then detached cells harvested. Dilutions were plated 
on agar plates. After 18 h of incubation at 37 oC the colony formation units (CFU) were 
counted.  
Dil-oxLDL binding study 
Dil-oxLDL uptake study was performed according to a published protocol with slight 
modification.37 HEK293 cells (1x106 cells) were seeded on ibidi slides and cultured for 24 
hours. Cells were transfected with plasmid for full length LOX-1 using Lipofectamine 3000 
(Thermo Fisher Scientific) according to the manufacturer’s protocol. HEK293 cells 
expressing LOX-1 and mock treated control were incubated with Dil-oxLDL (Sigma) 25 µL 
for 3 hours and washed three times with culture media and analyzed by confocal microscopy. 
To characterize an inhibitory potential cells were pre-treated for 30 minutes with either mAB 
anti LOX-1 or compound 6d before labeled oxLDL was added. Cells were treated with 
trypsin and subjected to flow cytometry for quantification of the fluorescence signal. 
Cell viability assay 
The most active molecules were analyzed in a cytotoxicity assay using HEK293 cells with 
the lactate dehydrogenase (LDH) release assay. Briefly, HEK293 cells were seeded in a 96-
wells plate at a concentration of 5 x103 cells/well and grown for 24 h. Cells were then treated 
with the compounds at concentrations ranging from 0.097-25 µM diluted in cell culture 
medium. To monitor 100% LDH release a detergent solution of 4% Triton-X-100 was used. 
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After 24 hrs of treatment the supernatant was collected for LDH activity measurements. The 
LDH assay kit (TaKaRa) was applied according to the manufacturer’s protocol. 
RESULTS AND DISCUSSION 
Synthesis and characterization of sulfated dendron polymer conjugates 
AB and ABA type dendron polymer conjugates (6a-d) were synthesized by coupling 
propargylated G1 and G2 oligoglycerol dendrons (3a and 3b) to monofunctional mPEG azide 
(10 kDa) and PEG bis azide (both 6 and 10 kDa, Table 1) via Cu catalyzed 1, 3 dipolar azide-
alkyne cycloaddition reaction (Figure 2).38 Oligoglycerol dendrons (G1, G2) were 
propargylated by propargyl bromide (Scheme 1) and purified via column chromatography 
following the procedure reported elsewhere.39 Similarly PEG bis azide (6 and 10 kDa) and 
mPEG-azide (10 kDa) were synthesized in two steps by mesylation of hydroxy groups and 
substitution by azide as reported before.40 A Cu assisted 1,3- dipolar cycloaddition reaction 
was monitored by FTIR (Figure S25) and continued until the disappearance of the azide peak 
at 2105 cm-1. In addition, both side functionalization was confirmed using 1H-NMR 
comparing the peaks by the appearance of peak at 7.77 ppm to 4.23 ppm (Figure S7). 
Deprotection of protected dendron polymer conjugates (both AB and ABA type) lead to 
formation of hydroxy functionalized dendron polymer conjugates (Scheme 1). The 
disappearance of the peak at 1.39 ppm proved the successful deprotection of acetals (Figure 
S13). In addition, the formation of ABA dendron polymer conjugates were analyzed by 
MALDI–TOF MS (Figure 3A). The experimental peak molecular weights Mp (corresponding 
to the peak with the highest intensity in the MS distribution) are noted in Table S1 (column 
2). Mp of PEG-6k_OH is found to be 6298 Da, which corresponds to the 142 oliogooxy 
repeating units. If single oligoglycerol dendrons of generation 1 and 2 were coupled to 2a the 
expected peaks should be observed at masses 6624 and 6920 Da respectively (Figure 3A, 
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Table S3). Obviously, there is no incidence of mono-functionalized oligoglycerol dendron 
conjugated to PEG. The complete shifts of Mp from 6298 Da to the maxima at 6955 
(compound 5a) and 7417 Da (compound 5b) indicate the successful bi-functionalization 
(Figure 3a). The calculated molecular weights based on 1H NMR are reported in Table S1 
(column 3) where the average molecular weight of PEG was considered 6000. Subsequent 
sulfation of the hydroxy groups using the sulfur trioxide pyridine complex led to the 
formation of desired macromolecules (6a-f). The polymers were characterized by 1H-NMR 
(Figure S1-24). S content was determined by elemental analysis and full conversion of the 
hydroxy groups to sulfates were confirmed by comparing the S content value for 100% 
conversion versus the obtained experimental value (Table 1). The results indicated full 
conversion of the hydroxy to sulfates. The detailed procedure and characterization for the 
synthesis of the above mentioned polymers is provided in SI. 
Next, sizes of the polymers were measured in water by dynamic light scattering (DLS) (Table 
1, Figure 3B). From the DLS measurements it could be seen that the hydrodynamic diameter 
of the polymers increased going from G1 to G2 dendrons in the same series (6a to 6b, Table 
1). All polymers (6a-f) showed negative zeta-potentials (range -7 to -15 mV). In addition, the 
zeta-potential correlated with the dendron generation. The monovalent AB type polymers 
showed a comparatively low negative potential compared to ABA type copolymers when the 
dendron generations were the same due to less sulfate groups in the polymer.  
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Scheme 1. Schematic representation for the synthesis of AB and ABA type sulfated 
dendronized PEG polymers. The synthesis is shown for generation 1 oligoglycerol dendrons. 
A similar synthetic procedure was followed for sulfated G2 dendronized polymers, synthetic 
scheme shown in SI. 
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 6a 7 3.48 3.44 4.95±0.06  0.43 ± 0.24 -11.1 ± 0.91 181 
6b 8 5.40 5.79 7.75±1.17  0.50 ± 0.13 -14.3 ± 1.25 45.8
6c 11 2.24 2.24 6.59±0.15  0.49 ± 0.01 -12.6± 1.10 93.3 
 6d 12 3.79 3.99 7.35±0.56  0.45 ± 0.12 -15.0 ± 0.65 47.4 
6e 10 1.13 1.19 3.24±0.25  0.51 ± 0.06 -7.00 ± 0.20 No 
binding 
 6f 11 2.17 2.23 4.35±0.17  0.20±0.05  -9.26 ± 0.59 2440 
a obtained by 1HNMR 
b obtained by elemental analysis (combustion analysis) 
c calculated based on 1HNMR 
d obtained by DLS (volume average) 
e apparent binding affinities of soluble compounds to immobilized LOX-1 fusion (2CTLD-
Fc) determined by SPR 
Page 12 of 23






























































Figure 3. A) MALDI-TOF mass spectra of i) 6 kDa PEG-OH and bi-functionalization with 
ii) G1 and iii) G2 oligoglycerol dendrons, B) DLS plot by volume average
Expression of LOX-1 tetramers 
Oligomerization of LOX-1 is an essential feature for the ligand-binding activity at the cell 
surface.41 For the activity of recombinant soluble LOX-1 a multivalent protein is highly 
crucial.42 Therefore, a tetrameric species of soluble LOX-1 was expressed following the 
recommendation reported by Cao et al.42 to mimic receptor clustering. Details are given in 
the SI. In brief, constructs consisting of a duplicated C-type lectin domain (CTLD) of LOX-1 
were successfully transiently expressed as either secreted Fc-fusion protein 2CTLD-Fc or full 
length LOX-1 (fl LOX-1) membrane bound receptor in the mammalian cell line HEK293. 
The soluble LOX-1 fusion protein was purified by affinity chromatography on a Protein A 
column and successfully analyzed by SDS-PAGE and Western blotting (Figure S26). 
Binding analysis by surface plasmon resonance 
Binding studies were performed by surface plasmon resonance (SPR), where the 2CTLD-Fc 
protein was coupled to the Protein A sensor chip to a density of (1500 RU). Compounds 6a-f
were used as analytes and flushed over the functionalized chip surface. From the resulting 
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sensorgrams, individual rate constants (Fig S28-S32) and the dissociation constant at 
equilibrium KD were calculated (Table 1). Across the whole series of molecules an 
enhancement in LOX-1 binding was observed as the number of sulfates increased. 
Obviously, the dendron generation is important and correlates with receptor binding 
affinities. While compound 6e (G1 dendron with 4 sulfate groups) showed no binding, an 
affinity in the range of 2.44 µM was detected for compound 6f equipped with a G2 dendron 
(8 sulfate groups). A further affinity enhancement of about 50-fold was achieved by coupling 
two G2 dendrons to a bi-functional PEG linker. The finding that compounds 6b and 6d gave 
comparable KD values of 45.8 and 47.4 nM indicates that here the higher number of sulfate 
groups is important. Finally, it is interesting to note that the increase of binding affinity is 
only a factor of two when we compare molecules carrying two functional G1 moieties (6a
and 6c) versus those with G2 dendrons (6b and 6d). Obviously, both bi-functionalized 
compounds 6b and 6d are well suited to target the “basic spine” of arginine residues 
displayed at the LOX-1 dimer surface via electrostatic interactions.17,43 The charge density 
and hydrodynamic diameter seem to be absolutely important for an affine receptor 
recognition. Both the polymers 6b and 6d have similar hydrodynamic diameter of ~7 nm and 
the most negative zeta potentials (Table 1). On the other hand for 6c, the hydrodynamic 
diameter is comparable but the charge density is not sufficient to have a similar binding 
affinity. This is in line with our previous results, where we addressed the flat surface of the 
adhesion receptor L-selectin with diverse polyanions.44,45 So far, the accuracy of fit of 
compounds 6b and 6d to the LOX-1 surface cannot be finally answered and potential 
rebinding effects cannot be excluded.46,47 Nevertheless, both multivalent compounds show a 
remarkable receptor affinity while possessing only a limited number of functionalities. 
Competitive binding studies 
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LOX-1 acts as a scavenger receptor and is capable to bind different anionic molecules.48 
Clearance of aged red blood cells (aRBC) via LOX-1 expressing macrophages has been 
described.34 Phosphatidylserine (PS) flips to the outer leaflet of aged/apoptotic RBC seems to 
be the dominant target for LOX-1 and initiates phagocytosis by macrophages.49 Therefore 
competitive binding of the soluble receptor 2CTLD-Fc to aRBC as a model system was 
analyzed. A schematic overview of the assay is shown in the SI (Scheme S2). First, binding 
of the recombinant soluble LOX-1 fusion protein to aRBC was confirmed by co-incubation 
of receptor and ligand and subsequent visualization via a fluorescent probe; here the binding 
of FITC labelled Protein A to the Fc part of the fusion protein. The fluorescent image (Figure 
4A, i) clearly proved targeting of aged red blood cells, whereas native freshly prepared red 
blood cells (nRBC) were not addressed (Figure 4A, ii). In a following experiment the 
addition of inhibitors i. e. mAB anti LOX-1 (Figure 4A, iii) and compound 6d (Figure 4A, iv) 
at a concentration of 40 nM and 8 µM respectively, reduced the binding of 2CTLD-Fc to 
aRBC. The mAB served here as a positive control.34 For quantification of fluorescent signals 
FACS analyses were performed (Figure 4B) and the normalized results depicted in Figure 
3C. Binding of 2CTLD-Fc to aRBC was set to 100%, the negative control gave less than 0.5 
% of the fluorescence, and as a positive control the inhibitory antibody reduced the 
fluorescent signal to 20%. A dose-dependent inhibition was observed for compound 6d. at 
the highest concentration of 8 µM  the signal intensity was reduced to 40 %.
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Figure 4. Competitive binding of soluble LOX-1 (FITC labeled 2CTLD-Fc) to aged red 
blood cells. A) Fluorescence microscopy images: i) aRBC (positive control); ii) nRBC 
(negative control), iii) aRBC + mAB anti LOX-1; iv) aRBC + compound 6d. B) 
Corresponding FACS analyses. C) Dose-dependent inhibition of compound 6d. Values for 
each bar are the average mean from 3 separate experiments, ***P<0.05 
In a second in vitro model, binding of the pathogen E.coli (DH5α) to HEK293 cells 
expressing the membrane bound LOX-1 was analyzed. Interaction of Gram-positive as well 
as Gram-negative bacteria with LOX-1 has been described and again point to the versatility 
of this scavenger receptor.35 From the fluorescent images (Figure S34) it is obvious that the 
membrane bound LOX-1 is functionally expressed in transformed HEK293 cells and 
therefore competent for E. coli binding. Protein expression was confirmed by a Western-blot 
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analysis (SI, Figure S27).  At a concentration of 100 µg/mL compound 6d reduced the 
bacterial adhesion to approximately 50% (Figure S34, B) and Poly(I) nearly to background 
level. 
Dil-oxLDL binding study 
Binding and uptake of oxLDLwas investigated after a 3 hours incubation with LOX-1 
expressing HEK293 cells for and subsequent washing with culture medium. Confocal 
imaging (Figure 5) reveals that the cells expressing LOX-1 were able to bind and internalize 
Dil-oxLDL, whereas cells lacking LOX-1 did not show of Dil-oxLDL binding. Pre-
exposition of the cells expressing LOX-1 with the compound 6d (8 µM) caused a reduction 
in fluorescence intensity as showed in Figure 5A. FACS analyses (Figure 5B) and normalized 
fluorescence from trypsin treated cells (Figure 5C) indicate a 50% reduction of Dil-oxLDL 
uptake in the presence of 8 µM compound 6d. 
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Figure 5. Competitive binding of soluble Dil-oxLDL to LOX-1 expressing cells. A, confocal 
merged images of brightfield and red fluorescent Dil-oxLDL B, FACS analyses. C, 
quantification of fluorescent signals. (i) Dil-oxLDL with LOX-1 expressing cells (positive 
control); (ii) Dil-oxLDL with cells without LOX-1 (negative control); Dil-oxLDL with LOX-
1 expressing cells pre-incubated with (iii) compound 6d (8 µM); (iv) mAB anti LOX-1 (40 
nM). Values for each bar are average mean from 3 separate experiments, ***P<0.05 
Cytotoxicity evaluation 
The most active molecules were analyzed for cytotoxicity. Cell membrane integrity was 
analyzed by the release of cytosolic lactate dehydrogenase (LDH) release assay, from 
HEK293 cells. Here, 6b, 6d showed no harmful effect up to a concentration of 25 µM as 
shown in Figure S35. Hence, these molecules seems to be safe and applicable for further in
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vivo studies to investigate their potential as LOX-1 inhibitors in in model systems of 
atherosclerosis. 
CONCLUSION 
A series of sulfated dendronized multivalent ligands with PEG (6 and 10 kDa) as spacers 
were designed to target the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). 
For ligand binding experiments soluble LOX-1 was successfully expressed and purified as a 
tetravalent Fc-fusion protein containing 2 tandem CTLD domains per heavy chain (2CTLD-
Fc). In cell based assays full length LOX-1 was expressed as membrane anchored protein. As 
a result from SPR based binding assays it turned out that G2 dendrons carrying 8 sulfate 
groups were the more effective binders compared to G1 dendrons. Compounds carrying two 
G2 dendrons and bridged via a PEG spacer (6b, 6d) gave binding affinities in the low nM 
range (~50 nM) irrespective of the linker length. As a further proof of function competitive 
binding studies of compound 6d was demonstrated by inhibition of LOX-1 binding of aged 
red blood cells and a Gram-negative E. coli strain. Finally, compound 6d significantly 
reduced binding of the ligand oxLDL. Regarding its prominent role in atherosclerosis, our 
results might pave the way for a specific ligand design to develop an efficient strategy to 
block oxLDL uptake via targeting LOX-1. 
Supporting Information. Detailed synthetic procedure and characterization details, protocol 
for oxLDL preparation and FITC labeling of E. coli, 1HNMR spectra of synthesized 
compounds, SDS-PAGE and Western blot image for protein characterization, SPR data, 
fluorescence and bright field image for inhibition assay of LOX-1 with aRBC binding, 
fluorescence image and quantification graph for inhibition assay of LOX-1 with E. coli, 
graph for cytotoxicity evaluation. 
Page 19 of 23































































The authors thank the MULTI-APP ITN and Deutsche Forschungsgemeinschaft (SFB 765) 
for funding of this work and also acknowledge Katharina Goltsche for G1 and G2 dendron 
synthesis as well as Koichi Yamamoto MD, PhD (The department of geriatric and general 
medicine Osaka university graduate school of medicine) and Prof. Tatsuya Sawamura 
(Department of Physiology, Shinshu University School of Medicine) for providing full length 
LOX-1 plasmid. 
REFERENCES 
1. Brown, M. S.; Goldstein, J. L., Receptor-mediated endocytosis: insights from the
lipoprotein receptor system. Proc. Natl. Acad. Sci. U. S. A. 1979, 76 (7), 3330-7. 
2. Zani, I. A.;  Stephen, S. L.;  Mughal, N. A.;  Russell, D.;  Homer-Vanniasinkam, S.;
Wheatcroft, S. B.; Ponnambalam, S., Scavenger receptor structure and function in health 
and disease. Cells 2015, 4 (2), 178-201. 
3. Canton, J.;  Neculai, D.; Grinstein, S., Scavenger receptors in homeostasis and
immunity. Nat. Rev. Immunol. 2013, 13 (9), 621-34. 
4. Sawamura, T.;  Kume, N.;  Aoyama, T.;  Moriwaki, H.;  Hoshikawa, H.;  Aiba, Y.;
Tanaka, T.;  Miwa, S.;  Katsura, Y.;  Kita, T.; Masaki, T., An endothelial receptor for oxidized 
low-density lipoprotein. Nature 1997, 386, 73. 
5. Chen, M.;  Kakutani, M.;  Naruko, T.;  Ueda, M.;  Narumiya, S.;  Masaki, T.;
Sawamura, T., Activation-dependent surface expression of LOX-1 in human platelets. 
Biochem. Biophys. Res. Commun. 2001, 282 (1), 153-8. 
6. Yoshida, H.;  Kondratenko, N.;  Green, S.;  Steinberg, D.; Quehenberger, O.,
Identification of the lectin-like receptor for oxidized low-density lipoprotein in human 
macrophages and its potential role as a scavenger receptor. Biochem. J. 1998, 334 (1), 9. 
7. Mehta, J. L.;  Chen, J.;  Hermonat, P. L.;  Romeo, F.; Novelli, G., Lectin-like, oxidized
low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of 
atherosclerosis and related disorders. Cardiovasc. Res. 2006, 69 (1), 36-45. 
8. Chen, M.;  Masaki, T.; Sawamura, T., LOX-1, the receptor for oxidized low-density
lipoprotein identified from endothelial cells: implications in endothelial dysfunction and 
atherosclerosis. Pharmacol. Ther. 2002, 95 (1), 89-100. 
9. Lusis, A. J., Atherosclerosis. Nature 2000, 407 (6801), 233-41.
10. Glass, C. K.; Witztum, J. L., Atherosclerosis. Cell 2001, 104 (4), 503-516.
11. Steinbrecher, U. P., Receptors for oxidized low density lipoprotein. Biochim. Biophys.
Acta 1999, 1436 (3), 279-98. 
12. Brown, M. S.; Goldstein, J. L., Heart attacks: gone with the century? Science 1996,
272 (5262), 629. 
Page 20 of 23






























































13. Organization, W. H., The top 10 causes of death. Jnuary 2017 ed.; 2017.
14. Tabas, I.;  García-Cardeña, G.; Owens, G. K., Recent insights into the cellular biology
of atherosclerosis. The Journal of Cell Biology 2015, 209 (1), 13. 
15. Braunwald, E., Cardiovascular Medicine at the Turn of the Millennium: Triumphs,
Concerns, and Opportunities. N. Engl. J. Med. 1997, 337 (19), 1360-1369. 
16. Xie, Q.;  Matsunaga, S.;  Niimi, S.;  Ogawa, S.;  Tokuyasu, K.;  Sakakibara, Y.; Machida,
S., Human lectin-like oxidized low-density lipoprotein receptor-1 functions as a dimer in 
living cells. DNA Cell Biol. 2004, 23 (2), 111-7. 
17. Ohki, I.;  Ishigaki, T.;  Oyama, T.;  Matsunaga, S.;  Xie, Q.;  Ohnishi-Kameyama, M.;
Murata, T.;  Tsuchiya, D.;  Machida, S.;  Morikawa, K.; Tate, S., Crystal structure of human 
lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand 
recognition mode to OxLDL. Structure 2005, 13 (6), 905-17. 
18. Wang, X.;  Khaidakov, M.;  Ding, Z.;  Mitra, S.;  Lu, J.;  Dai, Y.; Mehta, J. L., Lectin-like
oxidized low-density lipoprotein receptor-1 (LOX-1) and cardiac fibroblast growth. 
Hypertension 2012, 60 (6), 1437-42. 
19. HaJeung Park, F. G. A., and Jeffrey C. Boyington‡, The 1.4 Å Crystal Structure of the
Human Oxidized Low Density Lipoprotein Receptor Lox-1*. THE JOURNAL OF BIOLOGICAL 
CHEMISTRY 2005, 280 (14), 13593-13599. 
20. Falconi, M.;  Ciccone, S.;  D'Arrigo, P.;  Viani, F.;  Sorge, R.;  Novelli, G.;  Patrizi, P.;
Desideri, A.; Biocca, S., Design of a novel LOX-1 receptor antagonist mimicking the natural 
substrate. Biochem. Biophys. Res. Commun. 2013, 438 (2), 340-5. 
21. Thakkar, S.;  Wang, X.;  Khaidakov, M.;  Dai, Y.;  Gokulan, K.;  Mehta, J. L.; Varughese,
K. I., Structure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density 
Lipoprotein. Sci. Rep. 2015, 5, 16740. 
22. Papp, I.;  Dernedde, J.;  Enders, S.;  Riese, S. B.;  Shiao, T. C.;  Roy, R.; Haag, R.,
Multivalent presentation of mannose on hyperbranched polyglycerol and their interaction 
with concanavalin A lectin. ChemBioChem 2011, 12 (7), 1075-83. 
23. Papp, I.;  Sieben, C.;  Sisson, A. L.;  Kostka, J.;  Bottcher, C.;  Ludwig, K.;  Herrmann, A.;
Haag, R., Inhibition of influenza virus activity by multivalent glycoarchitectures with 
matched sizes. ChemBioChem 2011, 12 (6), 887-95. 
24. Dernedde, J.;  Rausch, A.;  Weinhart, M.;  Enders, S.;  Tauber, R.;  Licha, K.;  Schirner,
M.;  Zügel, U.;  von Bonin, A.; Haag, R., Dendritic polyglycerol sulfates as multivalent 
inhibitors of inflammation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (46), 19679. 
25. Bhatia, S.;  Lauster, D.;  Bardua, M.;  Ludwig, K.;  Angioletti-Uberti, S.;  Popp, N.;
Hoffmann, U.;  Paulus, F.;  Budt, M.;  Stadtmuller, M.;  Wolff, T.;  Hamann, A.;  Bottcher, C.;  
Herrmann, A.; Haag, R., Linear polysialoside outperforms dendritic analogs for inhibition of 
influenza virus infection in vitro and in vivo. Biomaterials 2017, 138, 22-34. 
26. Dey, P.;  Bergmann, T.;  Cuellar-Camacho, J. L.;  Ehrmann, S.;  Chowdhury, M. S.;
Zhang, M.;  Dahmani, I.;  Haag, R.; Azab, W., Multivalent Flexible Nanogels Exhibit Broad-
Spectrum Antiviral Activity by Blocking Virus Entry. ACS nano 2018, 12 (7), 6429-6442. 
27. Ziem, B.;  Azab, W.;  Gholami, M. F.;  Rabe, J. P.;  Osterrieder, N.; Haag, R., Size-
dependent inhibition of herpesvirus cellular entry by polyvalent nanoarchitectures. 
Nanoscale 2017, 9 (11), 3774-3783. 
28. Bhatia, S.;  Camacho, L. C.; Haag, R., Pathogen Inhibition by Multivalent Ligand
Architectures. J. Am. Chem. Soc. 2016, 138 (28), 8654-66. 
Page 21 of 23






























































29. Chen, M.;  Narumiya, S.;  Masaki, T.; Sawamura, T., Conserved C-terminal residues
within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein 
binding. Biochem. J. 2001, 355 (Pt 2), 289-96. 
30. Hodgson, S. M.;  McNelles, S. A.;  Abdullahu, L.;  Marozas, I. A.;  Anseth, K. S.;
Adronov, A., Reproducible Dendronized PEG Hydrogels via SPAAC Cross-Linking. 
Biomacromolecules 2017, 18 (12), 4054-4059. 
31. Lin, C. C.; Anseth, K. S., PEG hydrogels for the controlled release of biomolecules in
regenerative medicine. Pharm. Res. 2009, 26 (3), 631-43. 
32. Sontjens, S. H.;  Nettles, D. L.;  Carnahan, M. A.;  Setton, L. A.; Grinstaff, M. W.,
Biodendrimer-based hydrogel scaffolds for cartilage tissue repair. Biomacromolecules 2006, 
7 (1), 310-6. 
33. Thakkar, S.;  Wang, X.;  Khaidakov, M.;  Dai, Y.;  Gokulan, K.;  Mehta, J. L.; Varughese,
K. I., Structure-based Design Targeted at LOX-1, a Receptor for Oxidized Low-Density 
Lipoprotein. Sci Rep 2015, 5, 16740. 
34. Oka, K.;  Sawamura, T.;  Kikuta, K.;  Itokawa, S.;  Kume, N.;  Kita, T.; Masaki, T., Lectin-
like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic 
cells in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (16), 9535-40. 
35. Shimaoka, T.;  Kume, N.;  Minami, M.;  Hayashida, K.;  Sawamura, T.;  Kita, T.;
Yonehara, S., LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria. J. 
Immunol. 2001, 166 (8), 5108-14. 
36. Weingart, C. L.;  Broitman-Maduro, G.;  Dean, G.;  Newman, S.;  Peppler, M.; Weiss,
A. A., Fluorescent labels influence phagocytosis of Bordetella pertussis by human 
neutrophils. Infect Immun. 1999, 67 (8), 4264-7. 
37. Sawamura, T.;  Kume, N.;  Aoyama, T.;  Moriwaki, H.;  Hoshikawa, H.;  Aiba, Y.;
Tanaka, T.;  Miwa, S.;  Katsura, Y.;  Kita, T.; Masaki, T., An endothelial receptor for oxidized 
low-density lipoprotein. Nature 1997, 386 (6620), 73-7. 
38. Kolb, H. C.;  Finn, M. G.; Sharpless, K. B., Click Chemistry: Diverse Chemical Function
from a Few Good Reactions. Angew. Chem. Int. Ed. Engl. 2001, 40 (11), 2004-2021. 
39. Wyszogrodzka, M., Haag, Rainer, A Convergent Approach to Biocompatible
Polyglycerol “Click” Dendrons for the Synthesis of Modular Core–Shell Architectures and 
Their Transport Behavior. Chem. - Eur. J. 2008, 14, 9202-9214. 
40. Dey, P.;  Hemmati-Sadeghi, S.; Haag, R., Hydrolytically degradable, dendritic
polyglycerol sulfate based injectable hydrogels using strain promoted azide–alkyne 
cycloaddition reaction. Polym. Chem. 2016, 7 (2), 375-383. 
41. Matsunaga, S.;  Xie, Q.;  Kumano, M.;  Niimi, S.;  Sekizawa, K.;  Sakakibara, Y.;
Komba, S.; Machida, S., Lectin-like oxidized low-density lipoprotein receptor (LOX-1) 
functions as an oligomer and oligomerization is dependent on receptor density. Exp. Cell. 
Res. 2007, 313 (6), 1203-14. 
42. Cao, W.;  Calabro, V.;  Root, A.;  Yan, G.;  Lam, K.;  Olland, S.;  Sanford, J.;  Robak, A.;
Zollner, R.;  Lu, Z. J.;  Ait-Zahra, M.;  Agostinelli, R.;  Tchistiakova, L.;  Gill, D.;  Harnish, D.;  
Paulsen, J.; Shih, H. H., Oligomerization is required for the activity of recombinant soluble 
LOX-1. FEBS J. 2009, 276 (17), 4909-4920. 
43. Park, H.;  Adsit, F. G.; Boyington, J. C., The 1.4 Å Crystal Structure of the Human
Oxidized Low Density Lipoprotein Receptor Lox-1. J. Biol. Chem. 2005, 280 (14), 13593-
13599. 
Page 22 of 23






























































44. Weinhart, M.;  Groger, D.;  Enders, S.;  Dernedde, J.; Haag, R., Synthesis of dendritic
polyglycerol anions and their efficiency toward L-selectin inhibition. Biomacromolecules 
2011, 12 (7), 2502-11. 
45. Weinhart, M.;  Groger, D.;  Enders, S.;  Riese, S. B.;  Dernedde, J.;  Kainthan, R. K.;
Brooks, D. E.; Haag, R., The role of dimension in multivalent binding events: structure-
activity relationship of dendritic polyglycerol sulfate binding to L-selectin in correlation with 
size and surface charge density. Macromol. Biosci. 2011, 11 (8), 1088-98. 
46. Fasting, C.;  Schalley, C. A.;  Weber, M.;  Seitz, O.;  Hecht, S.;  Koksch, B.;  Dernedde,
J.;  Graf, C.;  Knapp, E.-W.; Haag, R., Multivalency as a Chemical Organization and Action 
Principle. Angewandte Chemie International Edition 2012, 51 (42), 10472-10498. 
47. Krishnamurthy, V. M.;  Estroff, L. A.; Whitesides, G. M., Multivalency in Ligand
Design. Fragment-based Approaches in Drug Discovery 2006. 
48. Yoshimoto, R.;  Fujita, Y.;  Kakino, A.;  Iwamoto, S.;  Takaya, T.; Sawamura, T., The
discovery of LOX-1, its ligands and clinical significance. Cardiovasc. Drugs Ther. 2011, 25 (5), 
379-91. 
49. Savill, J.;  Fadok, V.;  Henson, P.; Haslett, C., Phagocyte recognition of cells
undergoing apoptosis. Immunol. Today 1993, 14 (3), 131-6. 
Table of Contents (TOC)
Page 23 of 23































































Design and Synthesis of PEG-Oligoglycerol 
Sulfates as Multivalent Inhibitors for the Scavenger 
Receptor LOX-1 
Shalini Kumari,a Katharina Achazi,a Pradip Dey,a Rainer Haag,a Jens Derneddeb* 
a Institute for Chemistry and Biochemistry, Freie Universität Berlin, Takustr. 3, 14195 Berlin, 
Germany. 
b Charité-Universitätsmedizin Berlin, Institute of Laboratory Medicine, Clinical Chemistry and 
Pathobiochemistry, CVK Augustenburger Platz 1, 13353 Berlin, Germany 
List of content: 
1. Synthesis and characterization
1.1 Material
1.2 Synthetic procedure and characterization
2. Protocol for LDL particle isolation and oxidation.
3. Protocol for FITC labeling of E. coli
4. Schematic representation for the synthesis of AB and ABA type sulfated dendronized
PEG polymers. The synthesis is shown for generation 2 oligoglycerol dendrons (Scheme
S1)
5. 1HNMR spectra of the synthesized compounds and Tables S1-S3 for compound
characterization
6. Proof of protein expression
7. SPR derived binding isotherms
8. LOX-1 mediated binding to aRBC (microscopy images and schematic overview (Scheme
S2)
9. LOX-1 binding to E. coli
98
10. Compound toxicity
1. Synthesis and characterization
1.1 Materials 
All the reagents and solvents were purchased commercially and used without further 
purification. PEG of 6 kDa and 10 kDa were purchased from Roth chemicals. Oligoglycerol 
dendrons of generation 1 and 2 (G1 and G2) were synthesized according to a previously 
reported procedure1. SO3-pyridine complex was used as received from Fluka GmbH. NMR 
Spectra were recorded on JEOL ECX400, JEOL ECP500, BRUKER AV500 and Bruker 
AV700 spectrometers at 500 and 700 MHz for 1H NMR spectra and 100 MHz, 125 MHz and 
175 MHz for 13C NMR spectra. Chemical shifts are reported in parts per million (ppm) in 
relation to deuterated solvent peak calibration. IR spectra were recorded with a Nicolet 
AVATAR 320 FT-IR 5 SXC (Thermo Fischer Scientific, Waltham, MA, USA) with a DTGS 
detector from 4000 to 650 cm-1 by dropping a solution of the compound and letting it dry for 
few seconds.  
i) Synthesis of polyethyleneglycol-dimesylate (Compounds 1a, 1b)
PEG 6 kDa (5 g, 0.83 mmol, 1eq.) was dried overnight in high vacuum (HV) at 60 oC to remove 
traces of moisture. After cooling to room temperature the PEG was dissolved in 100 mL of 
anhydrous dichloromethane under argon atmosphere. Dry triethylamine (0.346 mL, 2.49 
mmol, 3 eq.) was added with stirring and the mixture was cooled in an ice bath, followed by 
the dropwise addition of mesyl chloride (0.192 mL, 2.49 mmol, 3 eq.). After stirring the 
reaction mixture for overnight at room temperature under argon it was added to a separating 
funnel containing dichloromethane (300 mL) and brine (50 mL). The organic layer was washed 
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twice with brine (2 x 50 mL), combined, dried over MgSO4 and concentrated in vacuum. The 
residue was precipitated in diethyl ether (250 mL) and stirred vigorously for 2 hours, filtered 
and washed again with diethyl ether to remove traces of triethylamine and methylsulfonyl 
chloride. Drying in high pressure yielded the desired product as nearly colourless solid.  
Polyethyleneglycol-dimesylate with molecular weight of 10 kDa was prepared analogously 
starting from PEG 10 kDa (5.10 g, 0.51 mmol, 1eq) whereas the equivalents of trimethylamine 
(0.42 mL, 3.06 mmol, 6 eq.) and methylsulfonyl chloride (0.23 mL, 3.06 mmol, 6eq) were 
increased due to higher sterical hindrance of the PEG chains.  
Compound 1a  
(4.11 g, yield: 80 %). 
1HNMR (500 MHz; DMSO-d6): ∂ 4.31-4.30 (m, 4 H, SO2OCH2CH2O), 3.63–3.33 (m, 590 H, 
PEG-backbone), 3.18 (s, 6H, CH3SO2) ppm. 
Compound 1b  
(3.83 g, yield: 74 %). 
1HNMR (500 MHz; DMSO-d6): ∂ 4.31-4.30 (m, 4 H, SO2OCH2CH2O), 3.68–3.35 (m, 995 H, 
PEG-backbone), 3.18 (s, 6H, CH3SO2) ppm. 
ii) Synthesis of polyethyleneglycol-diazide (Compounds 2a, 2b)
Compound 1a (3 g, 0.48 mmol, 1 eq.) was dissolved in 30 mL of DMF, sodium azide (93 mg, 
1.44 mmol, 3 eq.) was added and the mixture was stirred overnight at 60 °C. After removal of 
solvent the residue was dissolved in a mixture of dichloromethane (600 mL) and was washed 
twice with water (2 x 40 mL), and dried over anhydrous MgSO4. After evaporation of solvent, 
the residue was dissolved in water and was dialyzed against deionised water (MWCO: 2 kDa). 
Freeze-drying yielded the product as nearly colourless solid.  
Polyethyleneglycol-diazide with molecular weights of 10 kDa were prepared analogously 
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starting with Compound 1b (3 g, 0.29 mmol, 1 eq.) whereas the equivalents of sodium azide 
(94 mg, 1.45 mmol, 5eq.) were increased due to similar reason as stated above. 
Compound 2a  
(2.17 g, yield: 74 %). 
1HNMR (500 MHz; DMSO-d6): ∂ 3.68–3.38 (m, 578 H, PEG-backbone), 3.29-3.27 (t, 4H, 
OCH2CH2N3) ppm. 
Compound 2b  
(2.22 g, yield: 76 %). 
1HNMR (500 MHz; DMSO-d6): ∂ 3.65–3.39 (m, 902 H, PEG-backbone), 3.37-3.35 (t, 4H, 
OCH2CH2N3) ppm. 
iii) Synthesis of propargyl ethers of oligoglycerol dendron (Compounds 3a, 3b)
To a solution of protected generation one of oligoglycerol dendron [G1] (5 g, 15.60 mmol, 1 
eq.) in THF, sodium hydride (1.12 g, 46.80 mmol, 3 eq.) was added and stirred at 50 °C for 1h. 
To the above reaction mixture propargyl bromide (4.43 mL, 46.80 mmol, 3 eq.) was added 
slowly and stirred at room temperature overnight. The progress of the reaction was followed 
by TLC, after the completion of reaction excess of NaH was quenched by the drop wise 
addition of water while keeping the reaction flask in an ice bath. The reaction mixture was 
concentrated under reduced pressure and diluted with water. The compound was extracted with 
DCM and the organic layer was combined and dried over anhydrous MgSO4. The reaction 
mixture was concentrated and purified by column chromatography to obtain a pale yellow 
liquid.  
Similar procedure was opted for the synthesis of Compound 3b, starting with protected 
generation two of oligoglycerol dendron [G2] (5 g, 7.17 mmol, 1 eq.).  
Compound 3a  
(3.91 g, yield: 70 %) 
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1HNMR (500 MHz; CDCl3): δ 4.33-4.14 (m, 4H, -CHCH2OC(CH3)2), 4.06-3.97 (m, 2H, -
CHCH2OC(CH3)2), 3.83-3.45 (m, 11H, dendron), 2.96-2.90 (m, 1H, CHCCH2-), 1.32 (s, 6H, -
CCH3), 1.27 (s, 6H, -CCH3).  
MS (ESI) m/z = calculated for [C18H30O7Na]+: 381.1884; found: 381.2093. 
Compound 3b  
(3.79 g, yield: 72 %) 
1HNMR (500 MHz; CDCl3): δ 4.32-4.22 (m, 6H, -CHCH2OC(CH3)2), 4.05-4.02 (m, 4H, -
CHCH2OC(CH3)2), 3.73-3.46 (m, 27H, dendron), 2.42-2.41 (m, 1H, CHCCH2-), 1.40 (s, 12H, 
-CCH3), 1.34 (s, 12H, -CCH3).  
MS (ESI) m/z = calculated for [C36H62O15Na]+: 757.3981; found: 757.3964. 
iv) Protocol for click reactions (Compounds 4a, 4b, 4c, 4d, 4e, 4f)
To a mixture of the PEG-bisazide (1 eq.) and propargylated dendron (3 eq.) in DMF, copper 
sulfate solution (0.5 eq., aq. 0.1M) and sodium ascorbate (2 eq., 0.2M) were added. The 
reaction mixture was stirred at room temperature overnight. After complete consumption of 
azide, checked by IR spectroscopy, stirring was stopped and solvent was removed under 
reduced pressure and diluted with water. Organic compound was extracted from the aqueous 
phase using DCM. The combined organic phase was washed with satd. EDTA solution and 
water and dried over anhydrous Na2SO4. After evaporation of solvent, the residue was 
dissolved in water/methanol and was dialyzed against water/methanol (50:50 v/v) followed by 
water (MWCO: 2 kDa). Freeze-drying yielded the product as nearly colourless solid. 
Compound 4a  
(0.84 g, yield: 77 %) 
1HNMR (500 MHz; CDCl3): δ 7.77 (m, 2H, triazole), 4.78-4.63 (m, 4H, -CHCH2OC(CH3)2), 
4.54-4.51 (m, 4H, OCH2-triazole), 4.23-4.20 (m, 4H, OCH2CH2-triazole), 4.02-4.01 (m, 4H, 
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OCH2CH2-triazole), 3.86-3.85 (m, 4H, -CHCH2OC(CH3)2), 3.72-3.54 (m, 915H, PEG-
backbone & dendron), 1.39-1.37 (s, 12H, -CCH3), 1.33-1.31 (s, 12H, -CCH3).  
Compound 4b  
(0.96 g, yield: 78 %)  
1HNMR (500 MHz; CDCl3): δ 7.71 (m, 2H, triazole), 4.76-4.49 (m, 12H, -CHCH2OC(CH3)2 
and OCH2-triazole), 4.23-4.20 (m, 8H, OCH2CH2-triazole), 4.02-3.85 (m, 16H, -
CHCH2OC(CH3)2 and OCH2CH2-triazole), 3.70-3.50 (m, 1168H, PEG-backbone & dendron), 
1.38 (s, 24H, -CCH3), 1.32 (s, 24H, -CCH3). 
Compound 4c  
(0.80 g, yield: 75 %) 
1HNMR (500 MHz; DMSO-d6): δ 8.03 (m, 2H, triazole), 4.65-4.63 (m, 4H, -
CHCH2OC(CH3)2), 4.52-4.49 (m, 4H, OCH2-triazole), 4.17-4.11 (m, 4H, OCH2CH2-triazole), 
3.99-3.94 (m, 4H, OCH2CH2-triazole), 3.82-3.80 (t, 4H, -CHCH2OC(CH3)2), 3.55-3.45 (m, 
1680H, PEG-backbone & dendron), 1.31 (s, 12H, -CCH3), 1.26 (s, 12H, -CCH3).  
Compound 4d  
(0.88 g, yield: 78 %) 
1HNMR (500 MHz; D2O): δ 8.14 (s, 2H, triazole), 5.75-5.73 (m, 4H, -CHCH2OC(CH3)2), 5.58-
5.56 (m, 4H, OCH2-triazole), 5.26-5.22 (m, 4H, OCH2CH2-triazole), 4.68-4.66 (m, 16H, -
CHCH2OC(CH3)2), 4.16-4.13 (m, 4H, OCH2CH2-triazole), (4.00-3.57 (m, 2199H, PEG-
backbone & dendron), 1.46 (s, 24H, -CCH3), 1.40 (s, 24H, -CCH3). 
Compound 4e  
(0.36 g, yield: 70 %)  
1HNMR (500 MHz; CDCl3): δ 8.07 (s, 1H, triazole), 4.81-4.75 (m, 2H, -CHCH2OC(CH3)2), 
4.62-4.57 (m, 2H, OCH2-triazole), 4.52-4.50 (m, 4H, OCH2CH2-triazole), 4.23-3.40 (m, 
1782H, PEG-backbone & dendron), 1.37 (s, 6H, -CCH3), 1.32 (s, 6H, -CCH3).  
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Compound 4f  
(0.38 g, yield:71 %)  
1HNMR (500 MHz; D2O): δ 8.15 (s, 1H, triazole), 4.43-4.35 (m, 8H, -CHCH2OC(CH3)2, 
OCH2-triazole and OCH2CH2-triazole), 3.90-3.43 (m, 1891H, PEG-backbone & dendron), 
1.49 (s, 12H, -CCH3), 1.43 (s, 12H, -CCH3).  
v) Deprotection of protected dendrons (Compounds 5a, 5b, 5c, 5d, 5e, 5f)
PEG conjugated with protected dendron was dissolved in 1% aq. TFA (10 ml) and stirred at 
room temperature overnight. Deprotection reaction was monitored using NMR by analysing 
the disappearance of acetal protons. After complete deprotection the solvent was removed and 
the compound was dissolved in water and dialyzed against water (MWCO: 2 kDa). Freeze-
drying yielded a nearly colourless solid product. 
Compound 5a  
(0.40 g, yield: 82 %) 
1HNMR (500 MHz; D2O): δ 8.14 (s, 2H, triazole), 4.84 (s, 4H, -CHCH2OH), 4.69-4.67 (m, 
4H, OCH2-triazole), 4.03-4.01 (m, 4H, OCH2CH2-triazole) 3.89-3.64 (m, 1255H, PEG-
backbone & dendron). 
Compound 5b  
(0.38 g, yield: 80 %) 
1HNMR (500 MHz; D2O): δ 8.14 (s, 2H, triazole), 4.84-4.83 (m, 8H, -CHCH2OH), 4.69-4.67 
(m, 4H, OCH2-triazole), 4.02-4.00 (m, 4H, OCH2CH2-triazole 3.92-3.47 (m, 778H, PEG-
backbone & dendron). 
Compound 5c  
(0.39 g, yield: 81 %) 
1HNMR (500 MHz; D2O): δ 8.13 (s, 2H, triazole), 4.85-4.84 (m, 4H, -CHCH2OH), 4.69-
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4.67(m, 4H, OCH2-triazole), 4.31-4.27 (m, 4H, OCH2CH2-triazole), 4.23-3.63 (m, 1166H, 
PEG-backbone & dendron) 
Compound 5d  
(0.37 g, yield: 77 %) 
1HNMR (500 MHz; CD3OD): δ 8.13 (s, 2H, triazole), 4.65-4.58 (m, 12H, -CHCH2OH, OCH2-
triazole), 3.96 (s, 4H, OCH2CH2-triazole), 3.82-3.36 (m, 1764H, PEG-backbone & dendron). 
Compound 5e  
(0.17 g, yield: 71 %) 
1HNMR (500 MHz; D2O): δ 8.10 (s, 1H, triazole), 5.15-5.13 (t, 2H, -CHCH2OH), 4.64-4.24(m, 
4H, OCH2-triazole, OCH2CH2-triazole), 3.97-3.36 (m, 1120H, PEG-backbone & dendron) 
Compound 5f  
(0.18 g, yield: 74 %) 
1HNMR (500 MHz; D2O): δ 8.16 (s, 1H, triazole), 5.51 (s, 4H, -CHCH2OH), 4.79-4.69 (t, 2H, 
OCH2-triazole), 4.04-4.02 (t, 2H, OCH2CH2-triazole), 3.80-3.40 (m, 1505H, PEG-backbone & 
dendron) 
vi) Sulfation of deprotected molecules (Compounds 6a, 6b, 6c, 6d, 6e, 6f)
After drying the molecules for 18 h under high vacuum at 60 °C, they were dissolved in dry 
DMF under inert conditions. The polymer solution was heated to 60 °C and sulfur trioxide 
pyridine complex (5 eq. per OH) dissolved in a minimum amount of dry DMF, added dropwise. 
The reaction mixture was stirred for 18 h at 60 °C and further for 48 h at room temperature and 
the reaction was quenched by adding 10 ml deionized water. To the aqueous solution 1 M 
NaOH was added immediately until a pH of 11 was reached. Solvent was removed under 
vacuum and was further purified by dialysis in saturated aqueous NaCl solution and water. 
Results achieved from elemental analysis: 
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Compound 6a  
(0.19 g, yield: 70 %) 
1HNMR (500 MHz; D2O): δ 8.18 (s, 2H, triazole), 4.75-4.74 (m, 4H, -CHCH2OSO3-Na+), 4.68-
4.67 (m, 4H, OCH2-triazole), 4.29-4.20 (m, 4H, OCH2CH2-triazole) 4.02-3.63 (m, 563H, PEG-
backbone & dendron). 
Compound 6b  
(0.22 g, yield: 73 %)  
1HNMR (500 MHz; D2O): δ 8.16 (s, 2H, triazole), 5.19-5.00 (m, 4H, -CHCH2OSO3-Na+), 4.70-
4.66 (m, 8H, OCH2-triazole, -CHCH2OSO3-Na+), 4.32-4.28 (m, 4H, OCH2CH2-triazole) 4.24-
3.57 (m, 704H, PEG-backbone & dendron). 
Compound 6c  
(0.18 g, yield: 70 %) 
1HNMR (500 MHz; CDCl3): δ 8.19 (s, 2H, triazole), 4.69-4.68 (m, 4H, -CHCH2OSO3-Na+), 
4.30-4.27(m, 4H, OCH2-triazole), 4.25-4.21 (m, 4H, OCH2CH2-triazole), 4.03-3.62 (m, 
1049H, PEG-backbone & dendron) 
Compound 6d  
(0.20 g, yield: 71 %) 
1HNMR (500 MHz; D2O): δ 8.18 (s, 2H, triazole), 4.75-4.69 (m, 8H, -CHCH2OSO3-Na+), 4.33-
4.30 (m, 4H, OCH2-triazole), 4.26-4.23(m, 4H, OCH2CH2-triazole), 3.98-3.54 (m, 1114H, 
PEG-backbone & dendron). 
Compound 6e  
(90 mg, yield: 62 %) 
1HNMR (500 MHz; D2O): δ 8.19 (s, 1H, triazole), 4.76-4.68 (m, 2H, -CHCH2OSO3-Na+), 4.29-




(0.10 g, yield: 66 %) 
1HNMR (500 MHz; D2O): δ 8.14 (s, 1H, triazole), 4.30-4.14 (m, 8H, -CHCH2OSO3-Na+, 
OCH2-triazole, OCH2CH2-triazole), 3.90-3.37 (m, 1072H, PEG-backbone & dendron) 
2. Protocol for LDL particle isolation and oxidation.
Native LDL was isolated according to previously reported protocol.2 Briefly, native LDL was 
isolated from human blood plasma by sequential ultracentrifugation (1.006 to 1.34 g/mL). 
Native LDL was oxidised by using CuSO4(5 µmol/L) in PBS at 37 oC for 24 hours. The oxLDL 
was purified by dialysis against PBS at 4 oC for 48 hours. 
3. Protocol for FITC labeling of E. coli
FITC labeling of E. coli was done as described in previously reported protocol. 3 E. coli bacteria 
were cultured in a volume of 5 mL and harvested by centrifugation at 10000 rpm speed for 10 
min at 4 oC. 10 mg of FITC (Sigma) was freshly dissolved in DMSO (1 mL). The bacterial 
pellet was re-suspended in 0.1 M sodium bicarbonate buffer at pH 9.0 and diluted to 1010 
cells/mL in a total of 1 mL of sodium bicarbonate buffer. To this bacterial suspension 0.2 µL 
of FITC stock solution was added and resuspended. The cells were incubated in the dark with 
shaking for 30 min at room temperature. The cells were washed 3 times with PBS to remove 
unbound dye and resuspended to a concentration of 107 cells/mL. 
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4. Scheme S1. Schematic representation for the synthesis of AB and ABA type sulfated
dendronized PEG polymers. The synthesis is shown for generation 2 oligoglycerol dendrons. 
5. Spectra:
Figure S1. 1H NMR of compound 1a 
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Figure S2. 1H NMR of compound 1b 
Figure S3. 1H NMR of compound 2a 
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Figure S4. 1H NMR of compound 2b 
Figure S5. 1H NMR of compound 3a 
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Figure S6. 1H NMR of compound 3b 
Figure S7. 1H NMR of compound 4a 
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Figure S8. 1H NMR of compound 4b 
Figure S9. 1H NMR of compound 4c 
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Figure S10. 1H NMR of compound 4d 
Figure S11. 1H NMR of compound 4e 
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Figure S12. 1H NMR of compound 4f 
Figure S13. 1H NMR of compound 5a 
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Figure S14. 1H NMR of compound 5b 
Figure S15. 1H NMR of compound 5c 
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Figure S16. 1H NMR of compound 5d 
Figure S17. 1H NMR of compound 5e 
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Figure S18. 1H NMR of compound 5f 
Figure S19. 1H NMR of compound 6a 
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Figure S20. 1H NMR of compound 6b 
Figure S21. 1H NMR of compound 6c 
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Figure S22. 1H NMR of compound 6d 
Figure S23. 1H NMR of compound 6e 
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Figure S24. 1H NMR of compound 6f 
Table S1. Elemental analysis data of sulfated compounds. 
Compound C S N H 
6a 52.04 3.48 1.65 8.84 
6b 44.60 5.40 1.24 6.62 
6c 48.70 2.24 1.07 8.55 
6d 49.39 3.79 0.63 7.98 
6e 19.47 1.03 0.41 4.09 
6f 20.57 2.17 0.56 4.17 
Table S2. Molecular weight of polymers 





6 kDa PEG-OH 6298 6 
6 kDa PEG-G1OH 6955 7 
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6 kDa PEG-G2OH 7417 8 
a obtained by MALDI TOF 
b calculated from 1H NMR and FTIR considering 100% conversion of starting molecular 
weights of 6 kDa as provided by manufacturer 
Table S3. Molecular weight of single oligoglycerol dendron conjugated PEG polymers 
Formula mol wt m(n): nmmonomer + 
mend groups + mcation mass 
(g/mol) 
HO-(CH2CH2O)n-H 44.0 ´ n + 18 + 23 6298 
N3-CH2CH2-(O-CH2CH2)n-1-[G1-OH] [(n-1) ´  44.05+84+28+278+23 6624 
N3-CH2CH2-(O-CH2CH2)n-1-[G2-OH] [(n-1) ´  44.05+84+28+574+23 6920 
   n = 142 
Figure S25. FTIR spectra of i) PEG-bisazide and ii) PEG-G1conjugate (G1OH-PEG10k-
G1OH) 
6. Proof of protein expression
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Figure S26. Expressed and purified proteins (2CTLD-Fc and Fc control) separated on a SDS-
PAGE A) Western blot analysis and B) stained with Coomassie blue under reducing and non-
reducing conditions. 
Figure S27. Expressed full length LOX-1 protein run on SDS-PAGE, analysed by Western 
blot under reducing condition. 
7. SPR sensorgrams derived binding isotherms to calculate binding affinities
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Figure S28. Isotherm for compound 6a. 
Figure S29. Isotherm for compound 6b. 
Figure S30. Isotherm for compound 6c. 
Figure S31. Isotherm for compound 6d. 
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Figure S32. Isotherm for compound 6f. 
5. LOX-1 mediated binding to aRBC
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Figure S33. 2CTLD-Fc binding to RBC. Fluorescence and brightfield image of (i) aRBC; (ii), 
nRBC ; (iii), aRBC preincubated with compound 6d; (iv), aRBC preincubated with compound 6f; 
(v) aRBC preincubated with  mAB.  
Scheme S2. Schematic illustration to monitor interaction of LOX-1 and aged RBC expressing 
phosphotidylserine (PS) in a competitive binding assay. 
5. LOX-1 binding to E. coli
Figure S34. A) First row: fluorescence image, second row: overlap of fluorescence and bright field 
image; i) FITC- labeled E. coli bound to full length LOX-1 expressing cells ii) FITC-E. coli without 
LOX-1 expressing cells and FITC- labeled E. coli bound to membrane inserted full length LOX-1 
expressing cells preincubated with iii) Poly(I) and iv) Compound 6d respectively. B) 
Quantification of E. coli (in terms of CFU counted) adhered to the LOX-1 positive cells in presence 
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and absence of Poly(I) (100 µg/mL) and compound 6d (100 µg/mL). Detached bacteria were 
harvested and dilutions transferred to agar plates. Colony forming units (CFU) were counted after 
cultivation. Values for each bar are average mean from 3 separate experiments, ***P<0.05 vs 
indicated bar. 
6. Compound toxicity
Figure S35. Cytotoxicity was measured using a LDH Cytotoxicity Assay Kit after exposing 
HEK293 cells to two different concentrations (25 µM and 100 µM) of compounds for 24 hours. 
Data are presented as mean ± SD; n = 3 (***P >0.05). 
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4  Summary and Conclusion 
 
Based on the previous insight about polyanions and their interaction with various 
biologically relevant proteins, in this thesis the aim was to develop sulfated multivalent 
architectures targeting inflammation and cardiovascular diseases by inhibiting involved 
receptors i.e. L-selectin and LOX-1 respectively.  
In the first part of thesis, a toolbox approach was developed with a possible variation of 
ligands and the subsequent ligand recognition was investigated. For the toolbox system, 
CDVs were functionalized non-covalently with different lectin recognizing ligands i.e. 
mannose containing ligands targeting ConA and sulfate bearing ligands targeting L-
selectin. As discussed earlier L- selectin is an adhesion protein that supports the leukocyte 
attachment to endothelial cells leading to enhancement of inflammation process. PSGL-1 
having an anionic sulphotyrosine residue is one of the physiological ligands which binds 
via electrostatic interaction to the positive charged region of L-, E-, and P- selectin. 
Targeting this electrostatic interaction, sulfated ligands having high negative charge density 
have been reported as potent binder to L-selectin which could block the interaction between 
leukocyte and endothelial cells. In order to have the multivalent supramolecular scaffold b-
cyclodextrin vesicles were non-covalently functionalized with sulfated ligands. The ligands 
were designed is such a way that on one side the structural motif was conjugated with one 
or two adamantly residues allowing the ligand to complex with b-cyclodextrin at the 
surface of cyclodextrin vesicles. On the other side of ligand sulphate groups were 
introduced. Adamantane can form inclusion complex with b-CD with an affinity of Ka ~ 
104 M-1 for 1:1 monovalent binding and two adamantane per ligand can lead to divalent 
binding with apparent affinity constant up to Ka ~ 107 M-1 and additional kinetic 
stablisation due to complexation. For the synthesis of the ligands glycerol based dendrons 
were synthesized according to published procedure and the focal hydroxyl group was 
converted to propargyl group using propargyl bromide. Propargylated glycerol based 
dendron was conjugated via copper catalyzed 1, 3 dipolar azide alkyne cycloaddition 
reaction to alkyne terminated adamantane having a linker of tetraethylene glycol. Further, 
the terminal acetal groups were cleaved off by using Dowex resin and the free hydroxyl 
group were sulfated using sulfur trioxide pyridine complex. For the synthesis of host part, 
the amphiphilic B-cyclodextrins were functionalized with alkyl and polyethylene glycol 
chains according previously reported protocol. The b-cyclodextrin vesicles were obtained 
by extrusion producing vesicles with a diameter in a range of 100-200 nm and the size and 
Summary and Conclusion 
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morphology was investigated by dynamic light scattering (DLS) and cryogenic 
transmission electron microscopy (cryo-TEM). The non-covalent host-guest interaction of 
the complex was investigated between the adamantly ligands and b-CD using 1:1 ratio by 
isothermal titration calorimetry (ITC). The sulfated and non-sulfated ligands were analyzed 
to observe the effect of sulfation on the thermodynamic parameters. A reasonable binding 
affinity (Ka ~ 104 M-1) was observed for all the ligands. The sulfated ligands and respective 
CDV were analyzed for the binding with L-selectin by microscale thermophoresis (MST). 
The sulfated adamantly ligands without CDVs yields randomly fluctuating values for the 
MST response for the ligand titration range. While in presence of vesicles sigmoidal 
binding curves were obtained yielding a KD value of 34 µM and 25 µM for 4 and 8 sulfate 
groups, respectively. In this part of the thesis an enhanced binding towards L-selectin was 
achieved by multivalent display of the sulfated ligands on the CDV surface.  
In the second part of thesis, polysulfates was used to target LOX-1 a cell surface receptor 
involved in binding and internalization of oxLDL leading to plaque formation in arteries 
and initiation of atherosclerosis. Major ligand recognition/binding site is the hydrophobic 
tunnel in between the dimer of LOX-1 and the linearly aligned arginine residues stretched 
over the dimer known as “basic spine”. LOX-1 inhibition to antagonize oxLDL uptake 
could be potential therapeutic approach for cardiovascular disease and curtail the acute 
inflammatory response. Previously reported inhibitors for LOX-1 include small molecules 
screened by simulation, or the modified lipid-based molecules, for fitting to hydrophobic 
tunnel of the LOX-1. Till now there is no multivalent inhibitor available targeting LOX-1. 
In this part of thesis, a novel class of multivalent inhibitor based on AB type diblock and 
ABA type triblock dendron-polymer conjugates were developed for the inhibition of LOX-
1. The designing of polymer was done in such a way that it can bind to the basic amino 
acids in the ligands binding site which is a stretch of approximately 7 nm. For complete 
shielding and expansion over the dimeric surface a flexible linker was required, which can 
cover a distance of 7 nm. For the inhibitor design the block A of the polymer was sulfated 
glycerol based dendron with varying number of sulfates based on the generation of the 
dendron and the block B was linear polyethylene glycol of 6 and 10 kDa. The synthesized 
polymers were analyzed in binding assay with LOX-1 by surface plasmon resonance (SPR). 
For the binding study LOX-1 was expressed as tetramers as oligomerization of recombinant 
soluble LOX-1 is highly crucial for the activity and high binding affinity with the ligands. 
From the analysis of binding affinities of the synthesized polymers we came to know that 
bifunctional molecules well suited to target the basic spine of arginine residues on the 
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dimer of LOX-1 and high number of sulfate is important for strong binding. Hence, charge 
density and hydrodynamic diameter plays an important role to recognize a potential 
inhibitor for LOX-1. The major ligand of LOX-1 includes oxLDL, bacteria, aged red blood 
cells. Phosphatidylserine expressed on aged RBC happens to be the dominant target for 
LOX-1 binding. A competitive binding of soluble LOX-1 to aged RBC was analyzed as a 
model system. The bound LOX-1 was visualized by FITC labelled protein A and pre-
incubation of LOX-1 with the polymers caused a reduction in binding to aged RBC. In 
another in vitro assay LOX-1 expressing on cell surface showed binding to Dil-oxLDL and 
the binding was reduced on pre-incubation of the cells with the sulfated polymers. 
Similarly, an assay was set-up to visualize the inhibition of binding of LOX-1 with FITC 
labelled E. coli in presence of sulfated architectures. As a conclusion we can say that the 
molecules with two G2 dendrons carrying 8 sulfates on each end of the PEG linker showed 
high affinity in low nanomolar (~50 nM) concentration. Further as a proof of function these 
polymers were able to inhibit the binding of LOX-1 to aged RBC, a Gram-negative E. coli 
strain and finally the major ligand oxLDL.  
In conclusion, sulfated multivalent architectures are potential choice while addressing 
inflammation or cardiovascular disease through targeting L-selectin to inhibit leukocyte 
adhesion to endothelial cells or by targeting LOX-1 to inhibit binding and uptake of 
oxLDL. Nonetheless, binding affinities are highly dependent on the number of the sulfate 
group, structure and stability of the scaffold and also on linker length. Still a lot of open 
questions needs to be answered regarding the specificity of these polymers and interaction 













5  Outlook 
 
The development of sulfated multivalent dendrons for inhibition of two different receptors 
has substantiated that the compounds can be used for receptor inhibition at low 
concentrations. However, the efficacy and target specificity must be improved. Non-
covalent supramolecular assemblies e. g. CD-Adamantane as scaffold for multivalent 
ligand presentation, due to their propensity of disintegration at micromolar concentration. 
Considering an application in vivo a robust, high affinity compound is wanted that 
outcompetes additional potential binding partners. Therefore, electrostatic interactions that 
perfectly fit the given receptor architecture might not be sufficient to provide specificity.  In 
the case of L-selectin binding, a sulfated dendron could be linked to a carbohydrate moiety 
that targets the sugar-binding site.  For LOX-1, the intrinsic hydrophobic tunnel of the 
dimer should be addressed in addition to the basic spine at the receptor surface. A sulfated 
dendron equipped with a short hydrophobic part should be evaluated. A detailed look to the 
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6  Abstract and Kurzzusammenfassung 
 
6.1  Abstract 
 
Within the scope of this thesis, multivalent sulfated polymers were synthesized and 
investigated concerning their targeting properties towards two proteins: L-selectin, a cell 
adhesion molecule expressed on leukocytes and LOX-1, a scavenger receptor from 
macrophages. Whereas L-selectin plays a dominant role in chronic diseases, LOX-1 can 
contribute to atherosclerosis. In both cases, a targeted intervention is desired.  
In the first part, b-cyclodextrin vesicles were non-covalently functionalized with 
oligosulfate-adamantyl conjugates as guest molecules. The supramolecular assemblies were 
evaluated for L-selectin binding in solution by microscale thermophoresis. An increase in 
binding affinity was observed with respect to the sulfate valency of the ligands. The 
adamantly conjugates with 4 and 8 sulfate groups revealed KD values of 34 and 25 µM, 
respectively.  Unfunctionalized vesicles and sulfate-adamantly conjugates alone did not 
show any effect. However, the complex stability was limited. 
In the second part, sulfated oligoglycerol dendrons were conjugated to polyethylene linkers 
yielding mono- and bi-functionalized compounds. For binding studies, a soluble 
recombinant fusion protein was expressed that carries two LOX-1 dimers. Targeting of the 
positively charged, linearly aligned arginine residue on the dimer surface was evaluates for 
all polymeric architectures by surface plasmon resonance and two of the molecules gave 
binding affinities in the low nM range (~50 nM). In cell-based assays the sulfated polymers 
were able to reduce the binding of soluble LOX-1 to target cells. Recognition of a 
physiological ligand, oxidized low density lipoprotein particle (oxLDL) by LOX-1 
expressing cells was reduced upon preincubation with the sulfated polymers.    
As a result, the work demonstrates that multivalent compounds enhance binding affinity 
and therefore, multivalency is a useful concept to interfere with planar biological surfaces.  
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6.2  Kurzzusammenfassung 
 
Ziel der Doktorarbeit war die Synthese multivalenter sulfatierter Polymere und 
Untersuchungen der Bindung an zwei Zielproteine: L-Selektin, einem Zell-
Adhäsionsmolekül, das auf Leukozyten exprimiert wird und LOX-1, ein Scavenger-
Rezeptor der auf Makrophagen vorkommt. Während L-Selektin eine wichtige Rolle bei 
chronischen Erkrankungen spielt, kommt LOX-1 eine zentrale Rolle bei der Entwicklung 
der Atherosklerose zu. In beiden Krankheitsbildern ist eine zielgerichtete medizinische 
Intervention wünschenswert. 
Im ersten Teil der Arbeit wurden b-Cyclodextrinvesikel mit Oligosulfat-
Adamantylkonjugaten als Gast-Moleküle nicht-kovalent funktionalisiert. Diese 
supramolekularen Systeme wurden in Lösung mittels mikroskalarer Thermophorese 
hinsichtlich ihrer L-Selektinbindung untersucht. Dabei wurde eine Steigerung der 
Bindungsaffinität in Abhängigkeit von der Anzahl an Sulfatgruppen nachgewiesen. Die 
Adamantylkonjugate mit 4 bzw. 8 Sulfatgruppen ergaben KD-Werte von 34 und 25 µM. 
Nicht funktionalisierte Vesikel und die sulfatierten Adamantylkonjugate allein zeigten 
keine Bindung. Auffällig war, dass die Stabilität der Komplexe begrenzt war. 
Im zweiten Teil der Arbeit wurden sulfatierte Oligoglyceroldendrone an mono- und bi-
funktionelle Polyethylenlinker konjugiert. Zur Untersuchung der Funktionalität der 
Konjugate wurde ein lösliches Fusionsprotein exprimiert, dass aus zwei LOX-1 Dimeren 
besteht. Die Bindung an eine positiv geladene, lineare Poly-Argininsequenz auf der 
Oberfläche des LOX-1 Proteins wurde mit allen synthetisierten Konjugaten mittels 
Oberflächenplasmonresonanz-Spektroskopie bestimmt. Zwei Konjugate zeigten dabei 
Bindungsaffinitäten im unteren nM Bereich (~50 nM). In zellbasierten Experimenten 
reduzierten die sulfatierten Polymere die Bindung des rekombinanten löslichen LOX-1 an 
Zielzellen. Durch Vorinkubation eines physiologischen Liganden, dem oxidierten 
Lipoprotein Partikel (oxLDL) mit den sulfatierten Polymeren konnte die Bindung des 
Liganden an membranständiges LOX-1 auf Zielzellen reduziert werden. 
Als Ergebnis zeigt die Arbeit, dass multivalente Systeme geeignet sind Bindungsaffinität zu 
erhöhen und Multivalenz ein geeignetes Konzept ist, um planare biologische Oberflächen 
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Scaffold. DOI: 10.1039/C8TB00922H, 1 – Authors equally contributed. 
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8.2  List of abbreviations 
 
ApoB  Apolipoprotein B 
Arg  Arginine 
AT1  Angiotensin 1 
Ang-II  Angiotensin II 
CD  Cyclodextrin 
CDV  Cyclodextrin Vesicle 
ConA  Concavallin A 
CTLD  C-type lectin like domain 
CRP  C-reactive protein 
Cryo-TEM Cryo- Transmission electron microscopy 
DF   Degree of functionalization 
Dil-oxLDL Dil labelled oxidised low density lipoprotein 
DLS  Dynamic light scattering 
DNA  Deoxy ribose nucleic acid 
dPG  Dendritic polyglycerol 
dPGS   Dendritic polyglycerol sulfate 
ECM  Extracellular matrix 
E.Coli  Escherichia Coli 
eNOS  Endothelial nitric oxide synthase 
FITC  Fluorescein isothiocyanate 
FDA  US food and drug administration 
GAG  glycosaminoglycan 
ICAM-1 Intracellular adhesion molecule-1 
IL  Interleukin 
ITC  Isothermal titration calorimetry 
Kd  Dissociation constant 
LDL  Lox density lipoprotein 
LPs  Lipoproteins 
LOX-1 Low density oxidized lipoprotein – 1  
lPG  Linear polyglycerol 
MST  Microscale thermophoresis 
mRNA Messenger ribose nucleic acid 
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NF-Kb  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NMR  Nuclear magnetic resonance 
OxLDL Oxidised low density lipoprotein 
PAMAM Poly(amido-amine) 
PEG  Polyethylene glycol 
PSGL-1 P-selectin glycoprotein ligand-1 
RBC  Red blood cell 
RNA  Ribose nucleic acid 
ROMP  Ring opening metathesis polymerization 
siRNA  Small interfering RNA 
sLea   Sialylated Lewisa 
sLex   Sialylated LewisX 
SPR   Surface plasmon resonance 
SR  Scavenger receptor 
TM  Transmembrane 
TNFα   Tumor necrosis factor α 
VCAM-1 Vascular cell adhesion molecule-1 
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